

# CLIA WAIVED **T-Dip Multi-Drug Urine Test Panel**

Catalogue No. See Box Label

# CLIA CATEGORIZATION: WAIVED URINE SCREENING TEST RESULTS AT 5 MINUTES

The SAFElife™ T-Dip Multi-Drug Urine Test Panel are competitive binding, lateral flow CONTENT OF THE KIT immunochromatographic assays for qualitative and simultaneous detection of Amphetamine, Secobarbital, Buprenorphine, Oxazepam, Cocaine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), Methylenedioxymethamphetamine, Methamphetamine, Morphine, Methadone, Oxycodone, Phencyclidine, Propoxyphene, Nortriptyline and Cannabinoids in human urine with below cutoff 2. concentrations and approximate detection time:

Drug (Identifier)	Drug (Identifier) Calibrator		Approximate Minimum Detection Time	Approximate Maximum Detection Time
Amphetamine (AMP500)	d-Amphetamine	500 ng/mL	2-7 hours	1-2 days
Amphetamine (AMP1000)	d-Amphetamine	1000 ng/mL	2-7 hours	1-2 days
Secobarbital (BAR)	Secobarbital	300 ng/mL	2-4 hours	1-4 days
Buprenorphine (BUP)	Buprenorphine	10 ng/mL	4 hours	1-3 days
Oxazepam (BZO)	Oxazepam	300 ng/mL	2-7 hours	1-2 days
Cocaine (COC150)	Benzoylecgonine	150 ng/mL	1-4 hours	2-4 days
Cocaine (COC300)	Benzoylecgonine	300 ng/mL	1-4 hours	2-4 days
EDDP	2-ethylidene-1,5- dimethyl-3,3-diphenyl- pyrrolidine	300 ng/mL	3-8 hours	1~3 days
Methylenedioxymetham phetamine (MDMA)	3,4- Methylenedioxymethamp hetamine	500 ng/mL	2-7 hours	2-4 days
Methamphetamine (MET500/mAMP500)	D(+)-Methamphetamine	500 ng/mL	2-7 hours	2-4 days
Methamphetamine (MET1000/mAMP1000)	D(+)-Methamphetamine	1000 ng/mL	2-7 hours	2-4 days
Morphine (MOP/OPI300)	Morphine	300 ng/mL	2 hours	2-3 days
Methadone (MTD)	Methadone	300 ng/mL	3-8 hours	1-3 days
Morphine (OPI2000)	Morphine	2000 ng/mL	2 hours	2-3 days
Oxycodone (OXY)	Oxycodone	100 ng/mL	4 hours	1-3 days
Phencyclidine (PCP)	Phencyclidine	25 ng/mL	4-6 hours	7-14days
Propoxyphene (PPX)	d-Propoxyphene	300 ng/mL	2 hours	2-3days
Nortriptyline (TCA)	Nortriptyline	1000 ng/mL	8-12hours	2-7 days
Cannabinoids (THC)	11-nor-Δ9-THC-9-COOH	50 ng/mL	2 hours	Up to 5+ days

SAFElife<sup>™</sup> T-Dip Multi-Drug Urine Test Panel offers any combinations from 2 to 15 drugs of abuse tests but 4. Re-cap the device and lay it flat on a clean, dry, non-absorbent surface. only one cutoff concentration under same drug condition will be included per device. It is intended for over-5. For the adulteration strip(s) if equipped, read results immediately, or at 30 seconds, or at 45 seconds the-counter and for prescription use. For *in vitro* diagnostic use.

The tests may yield positive results for the prescription drugs Buprenorphine, Nortriptyline, Oxazepam, Secobarbital, Propoxyphene, and Oxycodone when taken at or above prescribed doses. It is not intended to distinguish between prescription use or abuse of these drugs. Clinical consideration and professional 6. For the drug tests, read the results for the drugs at 5 minutes. Do not read after 30 minutes.

judgment should be applied to any drug of abuse test result, particularly in evaluating a preliminary positive result.

The tests provide only preliminary results. To obtain a confirmed analytical result, a more specific alternate chemical method must be used. Chromatography/Mass Spectrometry (GC/MS) or Liquid Chromatography/Tandem Mass Spectrometry (LC/MS-MS) is the recommended confirmatory method.

# WARNINGS AND PRECAUTIONS

- The test kit is for external use only. Do not swallow.
- 2. Discard after first use. The test kit cannot be used more than once.
- Do not use the test kit beyond expiry date.
- 4. Do not use the test kit if the pouch is punctured or not well sealed.
- 5. Keep out of the reach of children.
- 6. Read the drug test result at 5 minutes. Do not read the result after 30 minutes.

- 1. 25 Test devices, each in one pouch with one desiccant. The desiccants are for storage purposes only and are not used in the test procedure.
- One (1) Package Insert
- 3. 5 Adulteration Color Comparison Charts (If equipped).

# MATERIAL REQUIRED BUT NOT PROVIDED

- Urine collection cup
- 2. Timer or Clock

# STORAGE AND STABILITY

Store at 39°F-86°F (4°C-30°C) in the sealed pouch up to the expiration date. Keep away from direct sunlight, moisture and heat. DO NOT FREEZE.

# SPECIMEN COLLECTION

### WHEN TO COLLECT URINE FOR THE TEST?

You may collect urine samples in minimum detection time later after suspected drug use. Exactly when the urine sample is collected is very important in detecting any drug of abuse. This is because each drug is cleared by the body at different rates. Please refer to the minimum or maximum detection time of each drug in this instruction for use.

HOW TO COLLECT URINE?

Urinate directly into the urine collection cup.

# HOW TO DO THE TEST?

Test should be conducted between 65°F-86°F (18°C-30°C).

- Open the sealed pouch by tearing along the notch. Remove the test device from the pouch.
- absorbent end.
- Immerse the absorbent end into the urine specimen for approximately 10 seconds. Make sure that positive test result. the urine level is not above the Mark Line printed on the front of the device.
- and compare each adulterant pad to verify pad color is within acceptable range according to the The definition of the false positive test would be the instance where a substance is identified incorrectly by Adulteration Color Comparison Chart. If the results indicate adulteration, do not read the drug test are cross results. Obtain a new urine specimen again with new collection cup, and test again with new test device.



# Note: Results after more than 30 minutes may be not accurate and should not be read.

# READING THE RESULTS

## DRUGS TESTS:

### Negative (-)

A colored band is visible in each Control Region (C) and the appropriate Test Region (T). It indicates that of the test.

# Preliminary Positive (+)

A colored band is visible in each Control Region (C). No colored band appears in the appropriate Test adulteration. Region (T). It indicates a preliminary positive result for the corresponding drug of that specific test zone.

### Invalid

If a colored band is not visible in each of the Control Region (C) or a colored band is only visible in the Test Reaion (T), the test is invalid. Another test should be run to re-evaluate the specimen. If the new test still A urine specific gravity below 1.003 or above 1.025 is considered abnormal. provides an invalid result, please contact the distributor from whom you purchased the product. When calling, be sure to provide the lot number of the test.



### Note: There is no meaning attributed to line color intensity or width.

The preliminary positive test result does not always mean that a person took illegal drugs. The negative test result does not always mean that a person did not take illegal drugs. There could be a number of factors that affect the reliability of drug tests. Certain drugs of abuse tests are more accurate than others.

### What Is the False Positive Test?

The definition of the false positive test would be the instance where a substance is identified incorrectly by 2. Hold one side of the device with one hand. Use the other hand to pull out the cap and expose the SAFElife<sup>TM</sup> T-Dip Multi-Drug Urine Test Panel. The most common causes of the false positive test are cross reactants. Certain foods and medicines, diet plan drugs and nutritional supplements may cause the false

# What Is the False Negative Test?

reactants. Certain foods and medicines, diet plan drugs and nutritional supplements may cause the false positive test result

If suspect someone is taking drugs but get the negative test results, please test again at another time, or 4. What are the Common Street Names for the Drugs to be detected? test for different drugs.

# ADULTERATION CONTROL

### Expected Results

Creatinine (CR): Creatinine reacts with a creatinine indicator in an alkaline medium to form a purplishbrown color complex if creatinine in the urine is present at the normal level. The color intensity is directly proportional to the concentration of creatinine. A urine sample with creatinine concentration of less than 20 mg/dl produces a very light, or no pad color change, which indicates adulteration in the form of specimen dilution.

Glutaraldehyde (GL): Glutaraldehyde is not a natural component of human urine and it should not be present in normal urine. The presence of glutaraldehyde in the urine sample indicates the possibility of adulteration. However, false positive may result when ketone bodies are present in urine. Ketone bodies may appear in urine when a person is in ketoacidosis, starvation or other metabolic abnormalities.

Nitrite (NI): Although nitrite is not a normal component of urine, nitrite levels of up to 3.6 mg/dL may be found in some urine specimens due to urinary tract infections, bacterial contamination or improper storage. In this adulteration control, nitrite level above 15 mg/dL is considered abnormal.

Oxidants/Bleach (OX): The presence of Bleach and other oxidizing reagents in the urine is indicative of the concentration of the corresponding drug of that specific test zone is zero or below the detection limit adulteration since oxidizing reagents are not normal constituents of urine. Other oxidizing reagents include Hydrogen Peroxide, Ferricyanide, Persulfate, Pyridinium Chlorochromate etc.

pH (PH): Normal urine pH ranges from 4.5 to 8.0. Values below pH 4.0 or above pH 9.0 are indicative of

Specific Gravity (S.G.): The specific gravity test is based on the pKa change of certain pretreated polyelectrolytes in relation to the ionic concentration. The pad colors will change from dark blue to bluegreen in urine of low ionic concentration to green and yellow-green in urine of higher ionic concentration.

# TEST LIMITATIONS

- 1. This test has been developed for testing urine specimens only. No other fluids have been evaluated. DO NOT use this device to test anything but urine.
- 2. Adulterated urine specimens may produce erroneous results. Strong oxidizing agents such as bleach (hypochlorite) can oxidize drug analytes. If a specimen is suspected of being adulterated, obtain a new specimen
- 3. It is possible that technical or procedural errors, as well as other interfering substances in the urine sample may cause false results.
- 4. This test is a qualitative screening assay. It is not designed to determine the quantitative concentration of drugs or the level of intoxication.

### **QUESTIONS AND ANSWERS**

- What does the drug of abuse urine test do? These tests detect if one or more prescription or illegal drugs such as Amphetamine, Secobarbital, Buprenorphine, Oxazepam, Cocaine, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), Methylenedioxymethamphetamine, Methamphetamine, Morphine, Methadone, Oxycodone, Phencyclidine, Propoxyphene, Nortriptyline and Cannabinoids are present in urine.
- What is "cut-off level"? The cut-off level is the specified concentration of a drug in a urine sample. Above that concentration the test result is called positive, and below that concentration it is called negative.
- What are drugs of abuse?
  - Drugs of abuse are illegal or prescription drugs (for example, Oxycodone or Valium) that are taken for a non-medical purpose, including taking the medication for longer than your doctor prescribed or for a purpose other than what the doctor prescribed.

Drug	Common Street Names
Amphetamine (AMP)	Speed, Jelly Beans or Super Jellies, Hearts, Uppers, Pick me ups or Wake me ups, Wake ups, Get ups, Boot ups, Sparkles
Secobarbital (BAR)	Amytal, Downers, Nembutal, Phenobarbital, Reds, Red Birds, Red devils, Seconal, Tuninal, Yellowjackets
Buprenorphine (BUP)	Bupe, Subbies, Temmies
Oxazepam (BZO)	Benzos, Downers, Nerve Pills, Tranks
Cocaine (COC)	Blow, C, Candy, Coke, Do a line, Freeze, Girl, Happy dust, Mama coca, Mojo, Monster, Nose, Pimp, Shot, Smoking gun, Snow, Sugar, Sweet stuff, and White powder.
Methylenedioxymetham phetamine (MDMA)	Ecstasy, E, X, XTC, Adam, Clarity, Lover's Speed
Methamphetamine (MET/mAMP)	Speed, Ice, Chalk, Meth, Crystal, Crank, Fire, Glass
Methadone (MTD)	mixture, meth, linctus, green
Morphine (MOP/OPI)	Aunt Hazel, big H, black pearl, brown sugar, capital H, charley, china white, dope, good horse, H, hard stuff, hero, heroina, little boy, mud, perfect hiah, smack, stuff and tar.
Oxycodone (OXY)	OC, Ocycotton, OX, and Kicker
Phencyclidine (PCP)	Angel dust, belladonna, black whack, CJ, cliffhanger, crystal joint, Detroit pink, elephant tranquilizer, hog, magic, Peter Pan, sheets, soma, TAC, trank, white horizon and zoom.
Propoxyphene (PPX)	Darvon, Darvocet, Dolene, Propacet 100, Wygesic, SK-65, SK-65 APAP, Trycet, Genagesic, E-Lor, Balacet, Pain Killer, Pinks, Footballs, PP- Cap
Nortriptyline (TCA)	Blue angels, Blue birds, Vivactil, Anafranil, Janimine, Tofranil
Cannabinoids (THC)	420, Aunt Mary, baby, bobby, boom, chira, chronic, ditch, ganja, grass, greens, hash, herb, Mary Jane, nigra, Pot, reefer, rip, root, skunk, stack, torch, weed and zambi.

### How accurate is the test?

The tests are sensitive to drugs and accurate. These tests, however, are not as accurate as lab tests. In some cases, certain foods and drugs may cause false positives as well as false negatives for those who use drug-testing kits.

- If the test results are negative, can the conclusion be that the person is free of drugs? This means that if the sample was collected properly and if the test was performed according to direction, then none of the drug screened were present in the urine.
- Does a preliminary positive screen test mean that drugs of abuse have been found? This means that the test has reacted with something in the sample and the sample must be sent to the lab for a more accurate test.
- What should I do if the lab test confirms a positive result? If you have received a confirmed positive result, please consult with our staff on a proper course of action. We will help you identify counselors who can help you. It is important that you remain calm and do not react in a negative way to the situation. If you do not believe the test result, please consult with your physician. They will have your background medical history and be able to provide you with detailed information on both the test and the meaning of the result.
- What is the principle of SAFElife™ T-Dip Multi-Drug Urine Test Panel? SAFElife™ T-Dip Multi-Drug Urine Test Panel are competitive immunoassays that is used to screen for the presence of drugs of abuse in urine. When the test is activated, the urine is absorbed into the device by capillary action. Then flowing across the pre-coated membrane, it will be mixed with the respective drug antibody conjugates. If concentrations of sample drugs are below corresponding detected drugs' cutoff, respective drug antibody conjugates bind to the respective drug-protein conjugates immobilized in the Test Region (T) of the device. This produces a colored

Province       Province <th< th=""><th>D</th><th>and in test r</th><th>egion</th><th>that inc</th><th>dicates a n</th><th>egative result. O</th><th>n the contrary, if</th><th>concentrations</th><th>of sample drugs</th><th>300</th><th>A</th><th>- 10</th><th>15</th><th>13</th><th>1</th><th>0</th><th>95%</th><th>100</th><th>A - 10</th><th>18 11</th><th>0</th><th>0</th><th>97.5%</th></th<>	D	and in test r	egion	that inc	dicates a n	egative result. O	n the contrary, if	concentrations	of sample drugs	300	A	- 10	15	13	1	0	95%	100	A - 10	18 11	0	0	97.5%
	a	re at or ab	ove	corresp	onding de	etected drugs'	cutoff, the free	drugs of sam	ple bind to the		Viewer	+ 0	0	0	28	10	95%		Viewer + 0	0 1	29	10	97.5%
American and provide and p	re	spective d	rug ai	ntibody	/ conjugat	es. It prevents t	the respective o	drug antibody o	conjugates from		В	- 10	15	15	2	0	100%		B - 10	18 11	1	0	97.5%
The product of the p	b	nding to th	e resp	pective	drug-prot	ein conjugates i	mmobilized in th	ne Test Region (	T) of the device.		Viewer	+ 0	0	3	29	10	97.5%		Viewer + 0	0 0	29	10	97.5%
   	TI	nerefore, th	ere is	no colo	ored band i	in the test regio	n that indicates	a preliminary p	ositive result. To		С	- 10	15	12	1	0	92.5%		C - 10	18 12	1	0	100%
bit was not been support to the start of the	se	erve as a pro	ocedu	ire cont	trol, if the t	est has been pe	rformed properly	y, a colored bar	nd will appear at		Viewer	+ 0	0	2	31	9	100%		Viewer + 0	0 1	28	10	95%
Aut control       Aut control     Aut control     Aut control     Aut control     Aut control     Aut control       Aut control	th	e Control R	legior	n (C).							Δ	- 10	18	10	0	0	95%		Δ - 10	20 9	2	0	975%
Built<										600	Viewer	+ 0	0	1	30	0	075%	DCD -		0 1	20	10	075%
Note the specifie of the specif	QUALITY	CONTRO	)L							150	viewer	10	10	11	1	7	77.5%	25	P 10	20 0	27	10	77.3%
<ul> <li> <ul> <li></li></ul></li></ul>										150	В	- 10	18			0	97.5%	25	B - IU	20 9		0	97.5%
	Users sho	ould follow	the c	raoraac	riate feder	ral, state, and	local auidelines	concerning th	ne frequency of		Viewer	+ 0	0	2	30	9	97.5%		Viewer + 0	0 1	29	10	97.5%
	assavina	external au	ality	control	materials	Even though th	ere is an intern	al procedural o	ontrol line in the		С	- 10	18	10	1	0	95%		C - 10	20 9	1	0	97.5%
	test devi	calin the C	`ontro		n (C) the	use of externo	al controls is st	ronaly recomm			Viewer	+ 0	0	3	28	11	97.5%		Viewer + 0	0 2	31	8	97.5%
<ul> <li>A manual provide and based on the specific based on t</li></ul>	laborator	v tocting p	ractic		nfirm the t	tost procedure (	and to vorify pr	ongry recomm	manco Positivo		А	- 10	13	14	1	0	92.5%		A - 10	17 11	1	0	95%
<ul> <li>man and appropriate analysis processes with appropriate and appropriate and appropriate and appropriate approprise appropriate appropriate appropriate appropriate appropriat</li></ul>	and noac	y testing pi				est procedure (	han to verify pro	positivo and pa	agativo controls	coc	Viewer	+ 0	0	3	28	11	97.5%	PPX	Viewer + 0	0 2	31	8	97.5%
<ul> <li>A matrix is a law and l</li></ul>	the server	tive contro		ula give	e trie expe		nen testing the	positive and ne	egative controls,	300	В	- 10	13	14	1	0	92.5%	300	B - 10	17 11	1	0	95%
<ul> <li> <ul> <li></li></ul></li></ul>	the same	assay proc	eaure	e snouid	a be daopi	tea. External Co	ntroi (positive al	na negative) sn	ouid be run with		Viewer	+ 0	0	3	28	11	975%		Viewer + 0	0 2	31	8	97.5%
Number	eacn nev		rece	ivea, ea	acn new s	inipment and e	acn new opera	tor to determin	e that tests are		C	- 10	17	1/1	1	0	02.5%		C = 10	17 11	1	0	05%
Next         Next <th< td=""><td>working p</td><td>properly.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>Viewer</td><td>+ 0</td><td>0</td><td>14</td><td>70</td><td>0</td><td>10.0%</td><td></td><td></td><td>0 2</td><td>20</td><td>10</td><td>07.5%</td></th<>	working p	properly.									Viewer	+ 0	0	14	70	0	10.0%			0 2	20	10	07.5%
Part of the second s											viewer	+ 0	0	1	32	8	100%		viewer + 0	0 2	29	10	97.5%
Accurate         State	PERFOR	MANCE C	HAR/	ACTER	ISTICS						A	- 10	18	11	0	0	97.5%		A - 10	18 10		0	95%
Accuracy         Prove         Accuracy										EDDP	Viewer	+ 0	0	1	32	8	100%	TCA	Viewer + 0	0 2	29	10	97.5%
<ul> <li> <ul> <li></li></ul></li></ul>	Accuracy									300	В	- 10	18	11	0	0	97.5%	1000	B - 10	18 10	1	0	95%
											Viewer	+ 0	0	1	32	8	100%		Viewer + 0	0 2	29	10	97.5%
consignation         APP         Nume         Last heat base. Each SATE(in * T-Dip Mul-Drag Unite Test Pasce. Each SATE(in * T-Dip Mul-Drag Unite SATE(in * T-Dip Mul-Drag)	1520 (eigl	nty for each	n drug	) clinico	al urine sp	ecimens were a	nalyzed by GC-	MS or LC/MS-I	MS and by each		С	- 10	18	11	0	0	97.5%		C - 10	18 10	1	0	95%
Paral excessibly there users. block there (Lotter Section Paral excession)         Paral excession Paral excession Paral excession         Paral excession Paral excession         Para excession </td <td>correspor</td> <td>nding SAFE</td> <td>life™ <sup>-</sup></td> <td>T-Dip M</td> <td>Iulti-Drug</td> <td>Urine Test Pane</td> <td>el. Each SAFElife</td> <td>e™ T-Dip Multi-</td> <td>Drug Urine Test</td> <td></td> <td>Viewer</td> <td>+ 0</td> <td>0</td> <td>2</td> <td>30</td> <td>10</td> <td>100%</td> <td></td> <td>Viewer + 0</td> <td>0 2</td> <td>30</td> <td>10</td> <td>100%</td>	correspor	nding SAFE	life™ <sup>-</sup>	T-Dip M	Iulti-Drug	Urine Test Pane	el. Each SAFElife	e™ T-Dip Multi-	Drug Urine Test		Viewer	+ 0	0	2	30	10	100%		Viewer + 0	0 2	30	10	100%
Lass bar not the Scater, loc scater, locater l	Panel wa	s read by th	nree vi	iewers. S	Specimens	s were divided b	v concentration	into five catea	ories: Drug Free.		Δ	- 10	18	10	0	0	95%		Δ - 10	10 0	0	0	95%
Bit b	Less than	Half the C	utoff.	Near C	Cutoff Nea	ative. Near Cut	off Positive and	High Positive.	Results were as	мома	Viewer	+ 0	0	2	30	10	10.0%	THE		0 2	30	10	10.0%
Number	followed:		,		5					MDMA	viewer	1 10	10	2		10	05%	THC I		10 2		10	100%
Trug First         Result         Result         Result         Horican         Hear Cutoff (Between the Greater (Between the Gre	Tonowea.									500	В	- 10	18	10	0	0	95%	50	B - IU	19 9	0	0	95%
Choice Free         Mean         Case         Net of the cutoring the cutoring         Propertion (lateneerse)         Propertion (lateneerse)         Propertion (lateneerse)         Properity (lateneerse)         Properity (laten	Davis	Decul		Dente	1	Norm Cutoff	No an Costoff	Illinda	9/		Viewer	+ 0	0	2	30	10	100%		Viewer + 0	0 2	30	10	100%
I best         Prof         Prof        <	Drug	Resul	τ	Drug	Less	Near Cuton	Near Cuton	High	70		С	- 10	18	10	0	0	95%		C – 10	19 9	0	0	95%
Image: Propertical states of the constraint	lest			Free	than	Negative	Positive	Positive	Agreement		Viewer	+ 0	0	2	20	20	100%						
Image: Problem         The specific pr									1.1 00 /140				-	-									
Image: Problem         Function         end observed weight operation         end operation					нап	(Between	(Between	(Greater	with GC/MS		A	- 10	15	13	0	0	95%	Precision a	nd Sensitivity				
Image: Normeter in the state of th					the	(Between 50% below	(Between the cutoff	(Greater than 50%	with GC/MS or LC/MS	MET	A	- 10 + 0	15 0	13	0 20	0 20	95% 100%	Precision a	nd Sensitivity				
V         V         Cutoff         V         Cutoff         V         C         Cutoff         V         C         Cutoff         V         C					the Cutoff	(Between 50% below the cutoff	(Between the cutoff and 50%	(Greater than 50% above the	with GC/MS or LC/MS	MET 500	A Viewer B	- 10 + 0 - 10	15 0 15	13 2 13	0 20 0	0 20 0	95% 100% 95%	Precision a	nd Sensitivity ate the precision and	sensitivity, each	drug samples	were analyzed	at the followi
AMP         View         *         0         0         2         30         10         100%           AMP         View         *         0         0         1         30         10         100%           AMP         View         *         0         0         1         30         10         100%           View         *         0         0         1         30         10         100%           View         *         0         0         1         30         10         100%           View         *         0         0         1         30         0         90%         1         0         0         2         24         15         97%           More         *         0         0         1         30         0         90%         1         0         0         0         0         0         97%           More         *         0         0         1         30         0         97%         1         10         97%         10         10         97%         10         10         97%         10         10         97%         10         10 </td <td></td> <td></td> <td></td> <td></td> <td>the Cutoff</td> <td>(Between 50% below the cutoff and the</td> <td>(Between the cutoff and 50% above the</td> <td>(Greater than 50% above the cutoff)</td> <td>with GC/MS or LC/MS</td> <td>MET 500</td> <td>A Viewer B</td> <td>- 10 + 0 - 10 + 0</td> <td>15 0 15 0</td> <td>13 2 13 3</td> <td>0 20 0 20</td> <td>0 20 0 20</td> <td>95% 100% 95%</td> <td>Precision a To investig concentrat</td> <td>nd Sensitivity ate the precision and ions: cutoff - 100%, cuto</td> <td>sensitivity, each M - 75%, cutoff - 50</td> <td>drug samples )%, cutoff - 25%,</td> <td>were analyzed , , cutoff, cutoff +2!</td> <td>at the followi 5%, cutoff + 50</td>					the Cutoff	(Between 50% below the cutoff and the	(Between the cutoff and 50% above the	(Greater than 50% above the cutoff)	with GC/MS or LC/MS	MET 500	A Viewer B	- 10 + 0 - 10 + 0	15 0 15 0	13 2 13 3	0 20 0 20	0 20 0 20	95% 100% 95%	Precision a To investig concentrat	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto	sensitivity, each M - 75%, cutoff - 50	drug samples )%, cutoff - 25%,	were analyzed , , cutoff, cutoff +2!	at the followi 5%, cutoff + 50
Amp         View         I <td></td> <td></td> <td></td> <td></td> <td>the Cutoff</td> <td>(Between 50% below the cutoff and the cutoff)</td> <td>(Between the cutoff and 50% above the cutoff)</td> <td>(Greater than 50% above the cutoff)</td> <td>with GC/MS or LC/MS</td> <td>МЕТ 500</td> <td>A Viewer B Viewer</td> <td>- 10 + 0 - 10 + 0</td> <td>15 0 15 0</td> <td>13 2 13 3 12</td> <td>0 20 0 20</td> <td>0 20 0 20</td> <td>95% 100% 95% 100%</td> <td>Precision a To investig concentrat cutoff + 75%</td> <td>nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 5 and the cutoff + 100%.</td> <td>sensitivity, each iff - 75%, cutoff - 5( All concentrations v</td> <td>drug samples )%, cutoff - 25%, vere confirmed w</td> <td>were analyzed , cutoff, cutoff +2! vith GC/MS or LC</td> <td>at the followi 5%, cutoff + 50 /MS method. T</td>					the Cutoff	(Between 50% below the cutoff and the cutoff)	(Between the cutoff and 50% above the cutoff)	(Greater than 50% above the cutoff)	with GC/MS or LC/MS	МЕТ 500	A Viewer B Viewer	- 10 + 0 - 10 + 0	15 0 15 0	13 2 13 3 12	0 20 0 20	0 20 0 20	95% 100% 95% 100%	Precision a To investig concentrat cutoff + 75%	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 5 and the cutoff + 100%.	sensitivity, each iff - 75%, cutoff - 5( All concentrations v	drug samples )%, cutoff - 25%, vere confirmed w	were analyzed , cutoff, cutoff +2! vith GC/MS or LC	at the followi 5%, cutoff + 50 /MS method. T
MP         Verver         ·         0         0         1         330         100		Viewer	+	0	Cutoff	(Between 50% below the cutoff and the cutoff) 2	(Between the cutoff and 50% above the cutoff) 30	(Greater than 50% above the cutoff)	with GC/MS or LC/MS 100%	MET 500	A Viewer B Viewer C	- 10 + 0 - 10 + 0 - 10	15 0 15 0 15	13 2 13 3 12	0 20 0 20 0 20 0	0 20 0 20 0	95% 100% 95% 100% 92.5%	Precision a To investig concentrat cutoff + 75% study was p	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 5 and the cutoff + 100%. performed 2 runs / day ar	sensitivity, each ff - 75%, cutoff - 50 All concentrations v ad lasted 25 davs us	drug samples )%, cutoff - 25%, vere confirmed w ina three differer	were analyzed , cutoff, cutoff +2! vith GC/MS or LC, nt lots of the SAFE	at the followi 5%, cutoff + 50 /MS method. T :life™ T-Dip Mul
S0         B         ·         0         7         12         0         0         97         12         0         97		Viewer	+	0	Cutoff 0 17	(Between 50% below the cutoff and the cutoff) 2 11	(Between the cutoff and 50% above the cutoff) 30 0	(Greater than 50% above the cutoff) 10 0	with GC/MS or LC/MS 100% 95%	MET 500	A Viewer B Viewer C Viewer	- 10 + 0 - 10 + 0 - 10 + 0 + 0	15 0 15 0 15 0	13 2 13 3 12 2	0 20 0 20 0 20 0 24	0 20 0 20 0 15	95% 100% 95% 100% 92.5% 97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. berformed 2 runs /day ar rest Panel Tatally 3 ope	sensitivity, each off - 75%, cutoff - 50 All concentrations v nd lasted 25 days us vrotors participated	drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t	were analyzed , cutoff, cutoff +2! vith GC/MS or LC, nt lots of the SAFE the corresponding	at the followi 5%, cutoff + 50 /MS method. T ilife™ T-Dip Mul 2 SAFElife™ T-C
Viewer         +         0         0         1         30         10         100%           C         -         10         17         12         0         0         90%         95% </td <td>АМР</td> <td>Viewer A Viewer</td> <td>+ - +</td> <td>0 10 0</td> <td>Cutoff 0 17 0</td> <td>(Between 50% below the cutoff and the cutoff) 2 11 1</td> <td>(Between the cutoff and 50% above the cutoff) 30 0 30</td> <td>(Greater than 50% above the cutoff) 10 0 10</td> <td>with GC/MS           or LC/MS           100%           95%           100%</td> <td>MET 500</td> <td>A Viewer B Viewer C Viewer A</td> <td>- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0</td> <td>15 0 15 0 15 0 15 0 18</td> <td>13 2 13 3 12 2 10</td> <td>0 20 0 20 0 20 0 24 1</td> <td>0 20 0 20 0 15 0</td> <td>95% 100% 95% 100% 92.5% 97.5% 97.5%</td> <td>To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug</td> <td>nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 5 and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel Each of</td> <td>sensitivity, each off - 75%, cutoff - 50 All concentrations v otal lasted 25 days us prators participated the 3 operators tes</td> <td>drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t t 2 aliguate at e</td> <td>were analyzed , cutoff, cutoff +2! vith GC/MS or LC, the GC/MS or LC, the corresponding acch concentration</td> <td>at the followi 5%, cutoff + 50 /MS method. T /Ilife™ T-Dip Mul g SAFElife™ T-C up for each lat r</td>	АМР	Viewer A Viewer	+ - +	0 10 0	Cutoff 0 17 0	(Between 50% below the cutoff and the cutoff) 2 11 1	(Between the cutoff and 50% above the cutoff) 30 0 30	(Greater than 50% above the cutoff) 10 0 10	with GC/MS           or LC/MS           100%           95%           100%	MET 500	A Viewer B Viewer C Viewer A	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0	15 0 15 0 15 0 15 0 18	13 2 13 3 12 2 10	0 20 0 20 0 20 0 24 1	0 20 0 20 0 15 0	95% 100% 95% 100% 92.5% 97.5% 97.5%	To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 5 and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel Each of	sensitivity, each off - 75%, cutoff - 50 All concentrations v otal lasted 25 days us prators participated the 3 operators tes	drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t t 2 aliguate at e	were analyzed , cutoff, cutoff +2! vith GC/MS or LC, the GC/MS or LC, the corresponding acch concentration	at the followi 5%, cutoff + 50 /MS method. T /Ilife™ T-Dip Mul g SAFElife™ T-C up for each lat r
No.         1         10         17         12         0         0         975%           Mer         -         10         16         13         0         100%         -         0         2         2         4         1         0         975%           AMP         Vice         -         10         16         13         0         0         975%         0         0         2         0         0         975%         Mome         A         100         16         133         2         0         95%         Mome         -         10         10         10         975%         10         10         10         10         975%         10         10         10         10         10         10         10         975%         10         10         10         10         10         10         10         975%         10         10         10         10         10         10         975%         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         10         <	AMP 500	Viewer A Viewer B	+ - + -	0 10 0 10	number           the           Cutoff           0           17           0           17	(Between 50% below the cutoff and the cutoff) 2 11 1 1 2	(Between the cutoff and 50% above the cutoff) 30 0 30 0	(Greater than 50% above the cutoff) 10 0 10	with GC/MS or LC/MS 100% 95% 100% 97.5%	MET 500 MET	A Viewer B Viewer C Viewer A Viewer	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 + 0	15 0 15 0 15 0 18 0	13 2 13 3 12 2 10 2	0 20 0 20 0 20 0 24 1 24	0 20 0 20 0 15 0 15	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           97.5%	To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 5 and the cutoff + 100%. performed 2 runs / day ar Test Panel. Totally 3 ope Urine Test Panel. Each of Der day) for a total of SC	sensitivity, each off - 75%, cutoff - 50 All concentrations v d lasted 25 days us prators participated the 3 operators tes observations participated	drug samples %, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration of	were analyzed , cutoff, cutoff +2! vith GC/MS or LC the corresponding ach concentratic our lot of the SAFE	at the followi 5%, cutoff + 50 /MS method. T life™ T-Dip Mul g SAFElife™ T-C pon for each IoT un for Each IoT
New P         1         0 <td>AMP 500</td> <td>Viewer A Viewer B Viewer</td> <td>+ - + + + +</td> <td>0 10 0 10</td> <td>0 17 0 17 0</td> <td>(Between 50% below the cutoff and the cutoff) 2 11 1 1 12 1</td> <td>(Between the cutoff and 50% above the cutoff) 30 0 30 0 30</td> <td>(Greater than 50% above the cutoff) 10 0 10 0</td> <td>with GC/MS or LC/MS 100% 95% 100% 97.5% 100%</td> <td>MET 500 MET 1000</td> <td>A Viewer B Viewer C Viewer A Viewer B</td> <td>- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10</td> <td>15 0 15 0 15 0 18 0 18</td> <td>13 2 13 3 12 2 10 2 10</td> <td>0 20 0 20 0 24 1 24 1</td> <td>0 20 0 20 0 15 0 15 0 15 0</td> <td>95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%</td> <td>Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs</td> <td>nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. performed 2 runs / day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel</td> <td>sensitivity, each off - 75%, cutoff - 50 All concentrations v nd lasted 25 days us rators participated i the 3 operators tes 0 determinations per</td> <td>drug samples %, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e r concentration p</td> <td>were analyzed , cutoff, cutoff +2! vith GC/MS or LC, tl lots of the SAFE the corresponding ach concentratic per lot of the SAFE</td> <td>at the followi 5%, cutoff + 50 /MS method. T Ilife™ T-Dip Mul g SAFElife™ T-E n for each lot p Ilife™ T-Dip Mul</td>	AMP 500	Viewer A Viewer B Viewer	+ - + + + +	0 10 0 10	0 17 0 17 0	(Between 50% below the cutoff and the cutoff) 2 11 1 1 12 1	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30	(Greater than 50% above the cutoff) 10 0 10 0	with GC/MS or LC/MS 100% 95% 100% 97.5% 100%	MET 500 MET 1000	A Viewer B Viewer C Viewer A Viewer B	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10	15 0 15 0 15 0 18 0 18	13 2 13 3 12 2 10 2 10	0 20 0 20 0 24 1 24 1	0 20 0 20 0 15 0 15 0 15 0	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. performed 2 runs / day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel	sensitivity, each off - 75%, cutoff - 50 All concentrations v nd lasted 25 days us rators participated i the 3 operators tes 0 determinations per	drug samples %, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e r concentration p	were analyzed , cutoff, cutoff +2! vith GC/MS or LC, tl lots of the SAFE the corresponding ach concentratic per lot of the SAFE	at the followi 5%, cutoff + 50 /MS method. T Ilife™ T-Dip Mul g SAFElife™ T-E n for each lot p Ilife™ T-Dip Mul
Viewer         i         0         0         0         000         000         20         00         200         000         97.5%         000         000         000         97.5%         000         000         000         000         97.5%         000         000         000         000         97.5%         000 <td>AMP 500</td> <td>Viewer A Viewer B Viewer</td> <td>+ - + - + - +</td> <td>0 10 0 10 0</td> <td>num           the           Cutoff           0           17           0           17           0           17           0           17</td> <td>(Between       50% below       the cutoff       and the       cutoff)       2       11       12       1       12</td> <td>(Between the cutoff and 50% above the cutoff) 30 0 30 0 30</td> <td>(Greater than 50% above the cutoff) 10 0 10 0 10</td> <td>with GC/MS or LC/MS 100% 95% 100% 97.5% 100%</td> <td>MET 500 MET 1000</td> <td>A Viewer B Viewer C Viewer A Viewer B Viewer</td> <td>- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 + 0</td> <td>15 0 15 0 15 0 18 0 18 0 18 0</td> <td>13 2 13 3 12 2 10 2 10 2 10 2</td> <td>0 20 0 20 0 24 1 24 1 24</td> <td>0 20 0 20 15 0 15 0 15 0 15</td> <td>95% 100% 95% 100% 92.5% 97.5% 95% 95% 95% 97.5%</td> <td>Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine</td> <td>nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. berformed 2 runs / day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel.</td> <td>sensitivity, each off - 75%, cutoff - 5( All concentrations v na lasted 25 days us rotors participated t the 3 operators tes d determinations per</td> <td>drug samples " )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p</td> <td>were analyzed , cutoff, cutoff +2 with GC/MS or LC , th lots of the SAFE the corresponding ach concentratic per lot of the SAFE</td> <td>at the followi 5%, cutoff + 50 /MS method. T Ilife™ T-Dip Mul g SAFElife™ T-C n for each lot p Ilife™ T-Dip Mul</td>	AMP 500	Viewer A Viewer B Viewer	+ - + - + - +	0 10 0 10 0	num           the           Cutoff           0           17           0           17           0           17           0           17	(Between       50% below       the cutoff       and the       cutoff)       2       11       12       1       12	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30	(Greater than 50% above the cutoff) 10 0 10 0 10	with GC/MS or LC/MS 100% 95% 100% 97.5% 100%	MET 500 MET 1000	A Viewer B Viewer C Viewer A Viewer B Viewer	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 + 0	15 0 15 0 15 0 18 0 18 0 18 0	13 2 13 3 12 2 10 2 10 2 10 2	0 20 0 20 0 24 1 24 1 24	0 20 0 20 15 0 15 0 15 0 15	95% 100% 95% 100% 92.5% 97.5% 95% 95% 95% 97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. berformed 2 runs / day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel.	sensitivity, each off - 75%, cutoff - 5( All concentrations v na lasted 25 days us rotors participated t the 3 operators tes d determinations per	drug samples " )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p	were analyzed , cutoff, cutoff +2 with GC/MS or LC , th lots of the SAFE the corresponding ach concentratic per lot of the SAFE	at the followi 5%, cutoff + 50 /MS method. T Ilife™ T-Dip Mul g SAFElife™ T-C n for each lot p Ilife™ T-Dip Mul
A         -         10         16         15         0         0         9/2.%         Megative/sective	AMP 500	Viewer A Viewer B Viewer C	+ - + - +	0 10 0 10 0 10	num           the           Cutoff           0           17           0           17           0           17           0           17           0           17	(Between       50% below       the cutoff       and the       cutoff)       2       11       1       12       1       12       1	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 20	(Greater than 50% above the cutoff) 10 0 10 0 10 0	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5%	MET 500 MET 1000	A Viewer B Viewer C Viewer A Viewer B Viewer C	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10	15 0 15 0 15 0 18 0 18 0 18	13           2           13           3           12           2           10           2           10           2           10           2           10           2           10	0 20 0 20 0 24 1 24 1 24 1 24 1	0 20 0 20 0 15 0 15 0 15 0 15 0	95%           100%           95%           100%           92.5%           97.5%           95%           95%           95%           95%           95%           95%           95%           95%           95%           95%           95%           95%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel.	sensitivity, each off - 75%, cutoff - 5( All concentrations v ad lasted 25 days us reators participated the 3 operators tes 0 determinations per	drug samples " %, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p	were analyzed , cutoff, cutoff +2 with GC/MS or LC the Corresponding ach concentration per lot of the SAFE	at the followi 5%, cutoff + 50 /MS method. T liffe™ T-Dip Mul g SAFElife™ T-C n for each lot p liffe™ T-Dip Mul
AMP         Viewer         +         0         0         1         28         10         95%           C         -         10         16         13         2         0         95%           Viewer         +         0         0         29         10         975%           Viewer         +         0         0         11         28         10         95%           Viewer         +         0         0         0         0         975%         70         10         18         12         1         0         100%           Merer         +         0         0         1         28         11         975%         70         50         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0 <t< td=""><td>AMP 500</td><td>Viewer A Viewer B Viewer C Viewer</td><td>+ - + - + - + + - + + - + + + + + + + +</td><td>0 10 0 10 0 10 0</td><td>0 0 17 0 17 0 17 0 17 0</td><td>Usetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           12</td><td>(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30</td><td>(Greater than 50% above the cutoff) 10 0 10 0 10 0 10</td><td>with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 100% 97.5%</td><td>MET 500 MET 1000</td><td>A Viewer B Viewer C Viewer A Viewer B Viewer C</td><td>- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 + 0 + 0</td><td>15 0 15 0 15 0 18 0 18 0 18 0</td><td>13           2           13           3           12           2           10           2           10           2           10           0           0</td><td>0 20 0 20 0 24 1 24 1 24 1 24 1 24 24 24</td><td>0 20 0 20 0 15 0 15 0 15 0 15 0 10</td><td>95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           95%           95%           95%           95%           95%           95%           95%           95%           95%           95%           95%           95%</td><td>Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine</td><td>ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. berformed 2 runs / day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel.</td><td>sensitivity, each off - 75%, cutoff - 50 All concentrations v and lasted 25 days us arators participated the 3 operators tes 0 determinations per Number of</td><td>drug samples 7%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p</td><td>were analyzed , cutoff, cutoff +2: with GC/MS or LC that lots of the SAFE the corresponding ach concentratic per lot of the SAFE Results</td><td>at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul g SAFElife™ T-C n for each lot p life™T-Dip Mul</td></t<>	AMP 500	Viewer A Viewer B Viewer C Viewer	+ - + - + - + + - + + - + + + + + + + +	0 10 0 10 0 10 0	0 0 17 0 17 0 17 0 17 0	Usetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           12	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 100% 97.5%	MET 500 MET 1000	A Viewer B Viewer C Viewer A Viewer B Viewer C	- 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 - 10 + 0 + 0 + 0	15 0 15 0 15 0 18 0 18 0 18 0	13           2           13           3           12           2           10           2           10           2           10           0           0	0 20 0 20 0 24 1 24 1 24 1 24 1 24 24 24	0 20 0 20 0 15 0 15 0 15 0 15 0 10	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           95%           95%           95%           95%           95%           95%           95%           95%           95%           95%           95%           95%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine	ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. berformed 2 runs / day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel.	sensitivity, each off - 75%, cutoff - 50 All concentrations v and lasted 25 days us arators participated the 3 operators tes 0 determinations per Number of	drug samples 7%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p	were analyzed , cutoff, cutoff +2: with GC/MS or LC that lots of the SAFE the corresponding ach concentratic per lot of the SAFE Results	at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul g SAFElife™ T-C n for each lot p life™T-Dip Mul
No         B         -         10         16         13         2         0         975%         50         27         10         10         10         50         50/0	AMP 500	Viewer A Viewer B Viewer C Viewer A	+ - + - + - + - + +	0 10 0 10 0 10 0 10	O           0           17           0           177           0           177           0           177           0           170           0           177           0           170           0           170           0           170           0           16           16	(Between       50% below       the cutoff       and the       cutoff)       2       11       12       1       12       1       12       1       12       1       13	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 30	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 0	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 100% 97.5%	MET 500 MET 1000	A Viewer B Viewer C Viewer B Viewer C Viewer A	- 10 + 0 - 10 - 10	15 0 15 0 15 0 18 0 18 0 18 0 18	13           2           13           3           12           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           12	0 20 0 20 0 24 1 24 1 24 1 24 1 29 1	0 20 0 20 0 15 0 15 0 15 0 15 0 10 0	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           90%           97.5%           90%           90%           90%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Tes	ate the precision and ions: cutoff - 100%, cuto is and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of	sensitivity, each ff - 75%, cutoff - 50 All concentrations v and lasted 25 days us prators participated the 3 operators tes 0 determinations per Number of Determinations	drug samples 7%, cutoff – 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p	were analyzed , cutoff, cutoff +2 with GC/MS or LC nt lots of the SAFE the corresponding ach concentratio per lot of the SAFE Results Results	at the followi 5%, cutoff + 50 /MS method. T ilife™ T-Dip Mul g SAFElife™ T-C n for each lot p life™ T-Dip Mul
New         +         0         0         1         28         10         95%           C         -         10         16         13         2         0         95%           M         -         10         16         13         2         0         95%           M         -         10         10         10         29         11         100%         -         10         95%           M         -         10         19         100         0         0         0         2         28         12         100%         100%           Mew         +         0         0         0         0         2         28         10         10         975%           Mew         +         0         0         1         0         975%         10         18         10         0         975%           M         -         10         18         10         1         0         975%         96         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0         50/0         <	AMP 500	Viewer A Viewer B Viewer C Viewer A Viewer	+ - + - + - + - + - + - + - + - + - + -	0 10 0 10 0 10 0 10 0	O           0           17           0           17           0           17           0           17           0           17           0           17           0           17           0           17           0           16           0	Usetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           12           1           12           1           13           1	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 30 0 28	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 97.5% 95%	MET 500 MET 1000	A Viewer C Viewer A Viewer B Viewer C Viewer C Viewer A Viewer	- 10 + 0 - 10	15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0	13           2           13           3           12           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           0           12           0	0 20 0 20 0 24 1 24 1 24 1 24 1 29 1 29 1 29	0 20 0 20 0 15 0 15 0 15 0 15 0 10 10	95%           100%           95%           100%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Tes	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto is and the cutoff + 100%. berformed 2 runs / day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL)	sensitivity, each ff - 75%, cutoff - 50 All concentrations v to lasted 25 days us prators participated the 3 operators tes 0 determinations per Number of Determinations per Lot	drug samples 7%, cutoff – 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p	were analyzed , , cutoff, cutoff +2! with GC/MS or LC at lots of the SAFE the corresponding ach concentratic over lot of the SAFE Results legative/Positive Lot 2	at the followi 5%, cutoff + 50 /MS method. T ilife™ T-Dip Mul g SAFEIrie™ T-D on for each lot p life™ T-Dip Mul control to the form the form the form the f
C         -         10         16         13         2         0         97.5%           Vewer         +         0         0         1         29         11         010.6%           BAR         -         10         19         100         00         00         97.5%           Yewer         +         0         0         1         29         11         010.6%           Viewer         +         0         0         1         28         11         97.5%           Viewer         +         0         0         1         28         11         97.5%           Viewer         +         0         0         1         0         0         1         0         0         1         0 </td <td>AMP 500 AMP 1000</td> <td>Viewer A Viewer B Viewer C Viewer A Viewer B</td> <td>+ - + - + - + - + - + - + +</td> <td>0 10 0 10 0 10 0 10 0 10 0</td> <td>O           0           17           0           17           0           17           0           17           0           17           0           17           0           16           0           16</td> <td>Usetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13</td> <td>(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 28 28 2</td> <td>(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 0</td> <td>with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 95% 95% 95%</td> <td>MET 500 MET 1000</td> <td>A Viewer C Viewer A Viewer C Viewer C Viewer A Viewer R</td> <td>- 10 + 0 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -</td> <td>15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0</td> <td>13           2           13           3           12           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           12           0           12           0</td> <td>0 20 0 20 0 24 1 24 1 24 1 24 1 29 1 29 1</td> <td>0 20 0 20 15 0 15 0 15 0 15 0 15 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0</td> <td>95%           100%           95%           100%           92.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           90.0%</td> <td>Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500</td> <td>nd Sensitivity ate the precision and ions: cutoff - 100%, cuto &amp; and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0</td> <td>sensitivity, each off - 75%, cutoff - 5( All concentrations v ad lasted 25 days us irrators participated i the 3 operators tes o determinations per Number of Determinations per Lot 50</td> <td>drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p (N Lot 1 50/0</td> <td>were analyzed , cutoff, cutoff +22 with GC/MS or LC , tt lots of the SAFE the corresponding ach concentratic ber lot of the SAFE Results Results Lot 2 50/0</td> <td>at the followi 5%, cutoff + 50 /MS method. T ilife™ T-Dip Mul g SAFEIrie™ T-D on for each lot p ilife™ T-Dip Mul ilife™ T-Dip Mul b) Lot 3 50/0</td>	AMP 500 AMP 1000	Viewer A Viewer B Viewer C Viewer A Viewer B	+ - + - + - + - + - + - + +	0 10 0 10 0 10 0 10 0 10 0	O           0           17           0           17           0           17           0           17           0           17           0           17           0           16           0           16	Usetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 28 28 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 0	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 95% 95% 95%	MET 500 MET 1000	A Viewer C Viewer A Viewer C Viewer C Viewer A Viewer R	- 10 + 0 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0	13           2           13           3           12           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           12           0           12           0	0 20 0 20 0 24 1 24 1 24 1 24 1 29 1 29 1	0 20 0 20 15 0 15 0 15 0 15 0 15 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	95%           100%           95%           100%           92.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           90.0%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto & and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0	sensitivity, each off - 75%, cutoff - 5( All concentrations v ad lasted 25 days us irrators participated i the 3 operators tes o determinations per Number of Determinations per Lot 50	drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p (N Lot 1 50/0	were analyzed , cutoff, cutoff +22 with GC/MS or LC , tt lots of the SAFE the corresponding ach concentratic ber lot of the SAFE Results Results Lot 2 50/0	at the followi 5%, cutoff + 50 /MS method. T ilife™ T-Dip Mul g SAFEIrie™ T-D on for each lot p ilife™ T-Dip Mul ilife™ T-Dip Mul b) Lot 3 50/0
Viewer         +         0         0         1         29         11         100%           A         -         10         19         10         0         0         97.5%           Mar         -         10         19         10         0         97.5%           Viewer         +         0         0         1         28.7         1         0         100%         95%           Viewer         +         0         0         1         0         97.5%           Viewer         +         0         0         1         0         97.5%           Viewer         +         0         0         1         0         97.5%           Viewer         +         0         0         1         10         10         11         0         97.5%           Number         *         0         0         2         2         2         10         10         97.5%           Viewer         +         0         0         2         2         0         0         2         30         10         30         10         30         30         30         30         30         3	AMP 500 AMP 1000	Viewer A Viewer C Viewer A Viewer B Viewer	+ +	0 10 0 10 0 10 0 10 0 10 0 10 0	the Cutoff 0 17 0 17 0 17 0 17 0 17 0 16 0 16 0 0	IBetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           12           1           13           13           1           13           1	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 28 28 28	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 97.5% 95%	MET 500 MET 1000 MOP 300	A Viewer C Viewer A Viewer B Viewer A Viewer A Viewer B	- 10 + 0 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0	13           2           13           3           12           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           0           12           0           12           0	0 20 0 20 0 24 1 24 1 24 1 24 1 29 1 29 1 29 20 20 20 20 20 20 20 20 20 20 20 20 20	0 20 0 20 0 15 0 15 0 15 0 15 0 10 0 10 0 10 10 10 10 10 1	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           90%           97.5%           90%           97.5%           90%           97.5%           100%           97.5%           100%           97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Tes AMP 500	ate the precision and ions: cutoff - 100%, cuto & and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0 125	sensitivity, each off - 75%, cutoff - 5( All concentrations v ad lasted 25 days us virators participated the 3 operators tes determinations per Number of Determinations per Lot 50 50	drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p (N Lot 1 50/0 50/0	were analyzed , cutoff, cutoff +2 , ith GC/MS or LC , th GC/MS or the SAFE the corresponding ach concentratic ber lot of the SAFE Results Results Lot 2 50/0 50/0	at the followi 5%, cutoff + 50 /MS method. T liffe™ T-Dip Mul g SAFElife™ T-C n for each lot p ulife™ T-Dip Mul liffe™ T-Dip Mul b) Lot 3 50/0 50/0
A         -         10         19         10         0         0         97.5%           BAR         -         10         19         10         1         28         11         97.5%           B         -         10         19         100         1         28         11         97.5%           Viewer         +         0         0         1         28         11         97.5%           Viewer         +         0         0         1         0         97.5%           Viewer         +         0         0         1         0         97.5%           Viewer         +         0         0         1         0         97.5%           Viewer         +         0         0         2         27         12         97.5%           750         50         0/50 </td <td>АМР 500 АМР 1000</td> <td>Viewer A Viewer B Viewer C Viewer B Viewer C</td> <td>+ - + - + + - - + - - - + - - - - - - -</td> <td>0 10 0 10 0 10 0 10 0 10 0 10 0 10</td> <td>the Cutoff 0 17 0 17 0 17 0 16 0 16 0 16</td> <td>IBetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           13           13           1           13           1           13           13</td> <td>(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 28 28 2 28 28 2</td> <td>(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1</td> <td>with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 95% 97.5% 95% 95% 97.5%</td> <td>MET 500 MET 1000 MOP 300</td> <td>A Viewer C Viewer A Viewer B Viewer C Viewer A Viewer B Viewer</td> <td>- 10 + 0 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -</td> <td>15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0</td> <td>13       2       13       3       12       2       10       2       10       2       10       2       10       12       0       12       0       12       0       12       0       12       0       12       0</td> <td>0 20 0 20 0 24 1 24 1 24 1 24 1 29 1 29 1 29 1 29</td> <td>0 20 0 20 0 15 0 15 0 15 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0</td> <td>95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           100%           97.5%           100%           97.5%</td> <td>Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500</td> <td>ate the precision and ions: cutoff - 100%, cuto &amp; and the cutoff + 100%. Deerformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0 125 250</td> <td>sensitivity, each off - 75%, cutoff - 5( All concentrations v ad lasted 25 days us rators participated the 3 operators tes determinations per Number of Determinations per Lot 50 50 50</td> <td>drug samples 7%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p Lot 1 50/0 50/0 50/0</td> <td>were analyzed , cutoff, cutoff +2! with GC/MS or LC the Corresponding ach concentration ber lot of the SAFE legative/Positive Lot 2 50/0 50/0 50/0</td> <td>at the followi 5%, cutoff + 50 /MS method. T life™ T-Dip Mul g SAFElife™ T-D in for each lot p life™ T-Dip Mul e) Lot 3 50/0 50/0 50/0</td>	АМР 500 АМР 1000	Viewer A Viewer B Viewer C Viewer B Viewer C	+ - + - + + - - + - - - + - - - - - - -	0 10 0 10 0 10 0 10 0 10 0 10 0 10	the Cutoff 0 17 0 17 0 17 0 16 0 16 0 16	IBetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           13           13           1           13           1           13           13	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 28 28 2 28 28 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 95% 97.5% 95% 95% 97.5%	MET 500 MET 1000 MOP 300	A Viewer C Viewer A Viewer B Viewer C Viewer A Viewer B Viewer	- 10 + 0 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0	13       2       13       3       12       2       10       2       10       2       10       2       10       12       0       12       0       12       0       12       0       12       0       12       0	0 20 0 20 0 24 1 24 1 24 1 24 1 29 1 29 1 29 1 29	0 20 0 20 0 15 0 15 0 15 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           100%           97.5%           100%           97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500	ate the precision and ions: cutoff - 100%, cuto & and the cutoff + 100%. Deerformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0 125 250	sensitivity, each off - 75%, cutoff - 5( All concentrations v ad lasted 25 days us rators participated the 3 operators tes determinations per Number of Determinations per Lot 50 50 50	drug samples 7%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p Lot 1 50/0 50/0 50/0	were analyzed , cutoff, cutoff +2! with GC/MS or LC the Corresponding ach concentration ber lot of the SAFE legative/Positive Lot 2 50/0 50/0 50/0	at the followi 5%, cutoff + 50 /MS method. T life™ T-Dip Mul g SAFElife™ T-D in for each lot p life™ T-Dip Mul e) Lot 3 50/0 50/0 50/0
BAR 0         Viewer B         -         0         0         1         28         11         975%           MTD         0         0         1         28         11         975%           Viewer C         +         0         0         1         0         975%           Viewer A         -         0         0         2         10         18         10         1         0         975%           Viewer B         -         10         18         10         0         2         30         10         10         975%           Viewer B         - <th0< th="">         0         2</th0<>	AMP 500 AMP 1000	Viewer A Viewer B Viewer C Viewer B Viewer C Viewer C	+ - + + - + + - - + + - - + + - - - + + - - - + + -	0 10 0 10 0 10 0 10 0 10 0 10 0	O           0           17           0           17           0           17           0           17           0           16           0           16           0           16	IBetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13           1           13           1           13           1           13           1           13           1           13           1	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 28 28 2 28 28 2 29	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 97.5% 95% 97.5% 95% 97.5% 100%	MET 500 MET 1000 MOP 300	A Viewer C Viewer A Viewer B Viewer C Viewer A Viewer C	-         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10	15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18	13       2       13       3       12       2       10       2       10       2       10       0       12       0       12       0       12       0       12       0       12       0       12       12	0 20 0 20 0 24 1 24 1 24 1 24 1 24 1 29 1 29 1 29 1	0 20 0 20 0 15 0 15 0 15 0 15 0 10 0 10 0 10 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%           100%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. berformed 2 runs / day ar Test Panel. Totally 3 ope per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0 125 250 375	sensitivity, each ff - 75%, cutoff - 50 All concentrations v and lasted 25 days us prators participated i the 3 operators tes 0 determinations per Number of Determinations per Lot 50 50 50 50 50	drug samples 7%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p Lot 1 50/0 50/0 50/0 50/0	were analyzed , cutoff, cutoff +2 with GC/MS or LC that lots of the SAFE the corresponding ach concentratic per lot of the SAFE Results Results Lot 2 50/0 50/0 50/0 50/0	at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul g SAFElife™ T-C n for each lot p life™ T-Dip Mul e) Lot 3 50/0 50/0 50/0 50/0
MAX         Viewer         -         0         0         0         1         0/00         1         0/00         0/50	AMP 500 AMP 1000	Viewer A Viewer C Viewer A Viewer C Viewer C	+ - + - + - + - + +	0 10 0 10 0 10 0 10 0 10 0 10 0 10	O           0           17           0           17           0           17           0           16           0           16           0           16           0           16           0           16           0           16           0           16	Usetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13           1           13           1           10	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 28 28 2 28 28 2 28 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 95% 97.5% 95% 97.5% 95% 97.5% 100% 97.5%	MET 500 MET 1000 MOP 300	A Viewer C Viewer A Viewer B Viewer A Viewer A Viewer B Viewer C Viewer V C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer V V Viewer Viewer V V Viewer V Viewer V V V V V V V V V V V V V V V V V V V	-         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10	15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0	13       2       13       3       12       2       10       2       10       2       10       2       10       10       12       0       12       0       12       0       12       2       12       2	0           0           20           0           20           0           24           1           24           1           24           1           24           1           29           1           29           1           29           1           29           1           29           1           29           1           28	0 20 0 20 0 15 0 15 0 15 0 10 0 10 0 10	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500	ate the precision and ions: cutoff - 100%, cuto is and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0 125 250 375 500	sensitivity, each ff - 75%, cutoff - 50 All concentrations v and lasted 25 days us prators participated the 3 operators tes 0 determinations per Number of Determinations per Lot 50 50 50 50 50	drug samples 7%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p (N Lot 1 50/0 50/0 50/0 50/0 11/79	were analyzed , cutoff, cutoff +2 with GC/MS or LC that lots of the SAFE the corresponding ach concentration over lot of the SAFE Results Results Regative/Positive Lot 2 50/0 50/0 50/0 10/40	at the followi 5%, cutoff + 50 /MS method. T ilife™ T-Dip Mul g SAFElife™ T-C n for each lot p life™ T-Dip Mul ilife™ T-Dip Mul s) Lot 3 50/0 50/0 50/0 50/0 50/0 10/40
Normalization         Normalinstantintentent         Normalinstent <th< td=""><td>AMP 500 AMP 1000</td><td>Viewer A Viewer B Viewer C Viewer B Viewer C Viewer C</td><td>+ - + - + - + - + + +</td><td>0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0</td><td>O           0           17           0           17           0           17           0           17           0           16           0           16           0           16           0           16           0           16           0           16           0           16           0           19           0</td><td>Usetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13           1           13           1           13           10           1</td><td>(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 30 0 28 28 2 28 2 2</td><td>(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1</td><td>with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 95% 95% 95% 95% 95% 95% 95% 97.5% 100% 97.5% 97.5%</td><td>MET 500 MET 1000 MOP 300</td><td>A Viewer C Viewer A Viewer B Viewer C Viewer A Viewer C Viewer C Viewer A</td><td>- 10 + 0 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -</td><td>15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18</td><td>13       2       13       3       12       2       10       2       10       2       10       2       10       2       10       2       10       12       0       12       2       10</td><td>0           20           0           20           0           20           0           20           0           20           0           20           0           24           1           24           1           24           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           28           0</td><td>0 20 0 20 15 0 15 0 15 0 15 0 15 0 15 0 10 0 10 0 10 0 10 0 12 0 12 0 0 12 0 0 0 0 0 0 0 0 0 0 0 0 0</td><td>95%           100%           95%           100%           92.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           100%           97.5%           100%           97.5%           100%           95%</td><td>Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500</td><td>ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0 125 250 375 500 475</td><td>sensitivity, each off - 75%, cutoff - 5( All concentrations v ad lasted 25 days us rotors participated the 3 operators tes 0 determinations per 0 determinations per 0 determinations per Lot 50 50 50 50 50 50</td><td>drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p (N Lot 1 50/0 50/0 50/0 50/0 11/39 0/20</td><td>were analyzed , cutoff, cutoff +22 with GC/MS or LC the Corresponding ach concentratic ber lot of the SAFE Results Results Regative/Positive Lot 2 50/0 50/0 50/0 50/0 10/40 0/50</td><td>at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul 9) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 50/0 10/40 0/50</td></th<>	AMP 500 AMP 1000	Viewer A Viewer B Viewer C Viewer B Viewer C Viewer C	+ - + - + - + - + + +	0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0	O           0           17           0           17           0           17           0           17           0           16           0           16           0           16           0           16           0           16           0           16           0           16           0           19           0	Usetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13           1           13           1           13           10           1	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 30 0 28 28 2 28 2 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 95% 95% 95% 95% 95% 95% 95% 97.5% 100% 97.5% 97.5%	MET 500 MET 1000 MOP 300	A Viewer C Viewer A Viewer B Viewer C Viewer A Viewer C Viewer C Viewer A	- 10 + 0 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18	13       2       13       3       12       2       10       2       10       2       10       2       10       2       10       2       10       12       0       12       2       10	0           20           0           20           0           20           0           20           0           20           0           20           0           24           1           24           1           24           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           28           0	0 20 0 20 15 0 15 0 15 0 15 0 15 0 15 0 10 0 10 0 10 0 10 0 12 0 12 0 0 12 0 0 0 0 0 0 0 0 0 0 0 0 0	95%           100%           95%           100%           92.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           100%           97.5%           100%           97.5%           100%           95%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500	ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0 125 250 375 500 475	sensitivity, each off - 75%, cutoff - 5( All concentrations v ad lasted 25 days us rotors participated the 3 operators tes 0 determinations per 0 determinations per 0 determinations per Lot 50 50 50 50 50 50	drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p (N Lot 1 50/0 50/0 50/0 50/0 11/39 0/20	were analyzed , cutoff, cutoff +22 with GC/MS or LC the Corresponding ach concentratic ber lot of the SAFE Results Results Regative/Positive Lot 2 50/0 50/0 50/0 50/0 10/40 0/50	at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul 9) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 50/0 10/40 0/50
Viewer         *         0         0         1         28         11         97.5%           C         -         10         19         10         1         0         97.5%           C         -         10         19         10         1         0         97.5%           Marce         -         10         10         10         97.5%           Viewer         -         10         18         10         1         0         97.5%         10         18         10         0         97.5%           Viewer         -         10         18         10         0         0         97.5%         100         100         100%           Viewer         +         0         0         3         30         10         100%         100%         100%         100%         100%         100%	AMP 500 AMP 1000 BAR	Viewer A Viewer C Viewer A Viewer C Viewer C Viewer C Viewer C Viewer C	+ +	0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	the Cutoff 0 17 0 17 0 17 0 17 0 17 0 17 0 17 0	(Between           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13           1           13           1           13           1           13           1           10           10	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 30 0 28 2 28 2 28 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 95% 97.5% 95% 97.5% 95% 97.5% 97.5% 97.5% 97.5%	MET 500 MET 1000 MOP 300	A Viewer C Viewer A Viewer B Viewer A Viewer C Viewer A Viewer C Viewer A Viewer A	- 10 + 0 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0	13       2       13       3       12       2       10       2       10       2       10       2       10       2       10       2       10       2       10       2       10       0       12       0       12       10       12       10       1	0           0           20           0           20           0           20           0           20           0           20           0           24           1           24           1           24           1           24           1           29           1           29           1           29           1           29           1           28           0           27	0 20 0 20 0 15 0 15 0 15 0 15 0 15 0 10 0 10 0 10 0 10 0 12 0 12	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%           100%           95%           97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Tes AMP 500	ate the precision and ions: cutoff – 100%, cuto & and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0 125 250 375 500 625	sensitivity, each ff - 75%, cutoff - 5( All concentrations v ad lasted 25 days us irrators participated i the 3 operators tes 0 determinations per Number of Determinations per Lot 50 50 50 50 50 50 50 50 50 50	drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p <u>(N</u> Lot 1 50/0 50/0 50/0 50/0 11/39 0/50 0/70	were analyzed , cutoff, cutoff +22 with GC/MS or LC th GC/MS or LC the corresponding ach concentratic ber lot of the SAFE Results Results Results S0/0 50/0 50/0 50/0 10/40 0/50	at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul g SAFElife™T-C n for each lot p ulife™T-Dip Mul clife™T-Dip Mul clife™T-Dip Mul clife 0/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0
K         C         -         10         19         10         1         0         97.5%           V         4         0         0         2         28         10         95%           A         -         10         18         10         2         0         10         10         95%           A         -         10         18         10         2         0         95%           Viewer         +         0         0         2         30         10         100%         95%           Bup 10         18         10         2         0         95%         4         0         0         2         30         10         100%           Viewer         +         0         0         2         30         10         100%         95%         50/c	AMP 500 AMP 1000 BAR 300	Viewer A Viewer C Viewer A Viewer B Viewer C Viewer A Viewer B	+ +	0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	the Cutoff 0 17 0 17 0 17 0 17 0 17 0 16 0 16 0 16	IBetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           13           13           1           13           1           10           10	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 30 0 28 2 2 28 2 2 28 2 2 29 0 28 2 2 29 0 28 2 2 29 0 28	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 95% 97.5% 95% 97.5% 95% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5%	MET 500 MET 1000 300 MTD 300	A Viewer C Viewer A Viewer C Viewer A Viewer B Viewer C Viewer B Viewer B Viewer B	- 10 + 0 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18	13       2       13       3       12       2       10       2       10       2       10       2       10       12       0       12       0       12       0       12       0       12       10       12       10       11	0 20 0 20 0 24 1 24 1 24 1 24 1 29 1 28 28 1 29 1 29 1 28 28 1 28 28 1 29 1 29 1 28 28 1 28 1 29 1 28 1 1 28 1 1 28 1 1 28 1 1 28 1 1 28 1 1 28 1 1 28 1 1 1 1 1 1 1 1 1 1 1 1 1	0 20 0 20 0 15 0 15 0 15 0 15 0 10 0 10 0 10 0 12 0 12 0 0	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           100%           97.5%           100%           95%           97.5%           100%           95%           97.5%           100%           95%           97.5%           97.5%           100%           95%           97.5%           97.5%           97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto & and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0 125 250 375 500 625 750	sensitivity, each off - 75%, cutoff - 50 All concentrations v ad lasted 25 days us rators participated the 3 operators tes 0 determinations per 0 determinations per Lot 50 50 50 50 50 50 50 50	drug samples 7%, cutoff - 25%, vere confirmed wing three differer in the study of t ts 2 aliquots at e concentration p	were analyzed , cutoff, cutoff +2: vith GC/MS or LC the Corresponding ach concentration ber lot of the SAFE legative/Positive Lot 2 50/0 50/0 50/0 50/0 10/40 0/50 0/50	at the followi 5%, cutoff + 50 /MS method. T life™ T-Dip Mul g SAFElife™ T-D in for each lot p life™ T-Dip Mul s) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/
Viewer         +         0         0         2         28         10         95%           A         -         10         18         10         2         0         95%           Weiwer         +         0         0         2         0         95%           Viewer         +         0         0         2         30         10         100%           Viewer         +         0         0         2         30         10         100%         95%           Bit         -         10         18         100         0         0         95%           Viewer         +         0         0         2         30         10         100%           Viewer         +         0         0         0         0         95%         50/text	AMP 500 AMP 1000 BAR 300	Viewer A Viewer C Viewer A Viewer B Viewer C Viewer A Viewer B Viewer B Viewer	+ - - + + - - - - - - - - - - - - - - -	0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0 10 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	O           0           17           0           17           0           17           0           16           0           16           0           16           0           16           0           16           0           16           0           19           0           19           0	(Between           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13           1           13           1           13           1           10           1           10           1           10           1	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 28 2 28 2 28 2 28 2 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 97.5% 95% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5%	MET 500 MET 1000 300 MTD 300	A Viewer C Viewer A Viewer C Viewer C Viewer B Viewer C Viewer B Viewer B Viewer B Viewer B Viewer B Viewer C	- 10 + 0 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	15           0           15           0           15           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0           18           0	13       2       13       3       12       2       10       2       10       2       10       2       10       0       12       0       12       0       12       0       12       0       12       10       11       2	0           0           20           0           20           0           24           1           24           1           24           1           24           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           27	0 20 0 20 0 15 0 15 0 15 0 15 0 10 0 10 0 10 0 10 0 12 0 12 0 12	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500	nd Sensitivity ate the precision and ions: cutoff - 100%, cutc is and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel. t Approximate Concentration of Sample (ng/mL) 0 125 250 375 500 625 750 875	sensitivity, each off - 75%, cutoff - 50 All concentrations v and lasted 25 days us arators participated the 3 operators tes o determinations per Number of Determinations per Lot 50 50 50 50 50 50 50 50 50 50	drug samples 7%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p Lot 1 50/0 50/0 50/0 50/0 50/0 11/39 0/50 0/50	were analyzed , cutoff, cutoff +21 with GC/MS or LC that lots of the SAFE the corresponding acch concentration ber lot of the SAFE <b>Results</b> <b>Lot 2</b> 50/0 50/0 50/0 50/0 50/0 10/40 0/50 0/50	at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul g SAFElife™ T-Dip Mul s) Lot 3 50/0 50/0 50/0 50/0 10/40 0/50 0/50 0/50
A         -         10         18         10         2         0         95%           A         -         10         18         10         2         0         95%           Bup 10         4         0         0         2         28         10         95%           Bup 10         4         0         0         0         0         0         0         95%           Bup 10         18         10         2         28         10         95%         30         10         100%           Viewer         4         0         0         0         0         0         95%           Viewer         4         0         0         0         0         95%         30         10         100%           Viewer         4         0         0         0         33         30         10         100%           Viewer         4         0         0         0         0         0         0         92.5%           Kow         2         0         0         1         30         10         100%         100%         100%           Kow         2         0	AMP 500 AMP 1000 BAR 300	Viewer A Viewer C Viewer A Viewer C Viewer A Viewer B Viewer B Viewer C	+ - - - - - - - - - - - - - - - - - - -	0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 0 10 0 0 0 10 0 0 0 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	O           0           17           0           17           0           17           0           16           0           16           0           16           0           16           0           16           0           19           0           19           0           19           0           19	IBetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13           1           13           1           10           1           10           1           10           1           10           1           10	(Between           the cutoff           and 50%           above the           cutoff)           30           0           30           0           30           0           30           0           30           0           30           0           30           0           30           0           28           2           28           29           0           28           1           28           1	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 95% 100% 97.5% 100% 97.5% 100% 97.5% 95% 97.5% 95% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5%	MET 500 MET 1000 MOP 300 MTD 300	A Viewer C Viewer A Viewer B Viewer A Viewer C V Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer V Viewer V V V V V V V V V V V V V V V V V V V	-         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10	15           0           15           0           15           0           18           18           18	13       2       13       3       12       2       10       2       10       2       10       0       12       0       12       0       12       0       12       0       12       10       12       10       12       10       12       10       11       2       10	0           0           20           0           20           0           24           1           24           1           24           1           24           1           29           1           29           1           29           1           28           0           27           1           27           1	0 20 0 20 0 15 0 15 0 15 0 15 0 15 0 10 10 0 10 0 10 0 10 0 12 0 12 0 0 12 0 0 12 0 0 12 0 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 15 0 0 10 0 0 10 0 0 10 0 0 0 10 0 0 10 0 0 0 10 0 0 0 10 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500	nd Sensitivity ate the precision and ions: cutoff - 100%, cuto is and the cutoff + 100%. berformed 2 runs /day ar Test Panel. Totally 3 ope per day), for a total of 50 Test Panel. Approximate Concentration of Sample (ng/mL) 0 125 250 375 500 625 750 875 1000	sensitivity, each off - 75%, cutoff - 50 All concentrations v and lasted 25 days us rators participated i the 3 operators tes 0 determinations per Number of Determinations per Lot 50 50 50 50 50 50 50 50 50 50	drug samples )%, cutoff - 25%, vere confirmed wing three differer in the study of t ts 2 aliquots at e concentration p (N Lot 1 50/0 50/0 50/0 50/0 50/0 11/39 0/50 0/50 0/50	were analyzed , cutoff, cutoff +22 , ith GC/MS or LC , the softhe SAFE the corresponding ach concentratio per lot of the SAFE Results Results Results So/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 5	at the followi 5%, cutoff + 50 /MS method. T ilife™ T-Dip Mul g SAFElife™ T-C n for each lot p Ilife™ T-Dip Mul s) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 0/50 0/50 0/50 0/50
Viewer         +         0         0         2         28         10         95%           Bup 10         -         10         18         0         0         0         95%           Weight         -         10         18         10         0         0         95%           Viewer         +         0         0         0         0         0         95%           Viewer         +         0         0         0         0         0         95%           Viewer         +         0         0         0         0         95%           Viewer         +         0         0         0         0         0         95%           No         0         0         0         0         0         0         0         0         95%           No         0         0         0         0         0         0         0         0         95%           BZO         Viewer         +         0         0         1         30         10         100         100%           100         0         0         0         0         0         0         0	AMP 500 AMP 1000 BAR 300	Viewer A Viewer B Viewer A Viewer C Viewer A Viewer B Viewer B Viewer C Viewer C		0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0 10 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	the Cutoff 0 17 0 17 0 17 0 17 0 17 0 17 0 16 0 16	IBetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13           1           13           1           13           1           13           1           10           10           10           2	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 28 2 2 28 2 2 28 2 2 28 2 2 9 0 28 2 2 28 2 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 2 8 2 2 2 8 2 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 2 8 2 2 2 2 8 2 2 2 2 2 8 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 95% 100% 97.5% 100% 97.5% 100% 97.5% 95% 97.5% 95% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5%	MET 500 MET 1000 MOP 300 MTD 300	A Viewer B Viewer C Viewer B Viewer C Viewer C Viewer C Viewer C Viewer S Viewer C Viewer	- 10 + 0 - 10 - 10 + 0 - 10 - 10 - 10 - 10 - 10 - 10 - 10 -	15           0           15           0           15           0           18	13       2       13       3       12       2       10       2       10       2       10       2       10       2       10       2       10       2       10       2       10       12       0       12       2       10       12       2       10       11       2       10       2       10       2	0           0           20           0           20           0           20           0           20           0           20           0           20           0           24           1           24           1           29           1           29           1           29           1           29           1           29           1           28           0           27           1           27           1           27           1           27           1           27	0 20 0 20 0 15 0 15 0 15 0 15 0 15 0 10 0 10 0 10 0 10 0 12 0 12 0 12 0 12 0 12 12 0 12 12 10 10 10 10 10 10 10 10 10 10	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Tes AMP 500	Add Sensitivity           ate the precision and ions: cutoff - 100%, cuto & and the cutoff + 100%.           senformed 2 runs / day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel.           t         Approximate Concentration of Sample (ng/mL)           0         125           250         375           500         625           750         875           1000         0	sensitivity, each off - 75%, cutoff - 5( All concentrations v ad lasted 25 days us virators participated the 3 operators tes 0 determinations per 0 determinations per 0 determinations per Lot 50 50 50 50 50 50 50 50 50 50 50 50 50	drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p (N Lot 1 50/0 50/0 50/0 50/0 50/0 11/39 0/50 0/50 0/50 0/50 50/0	were         analyzed           , cutoff, cutoff +2i           ith GC/MS or LC           th lots of the SAFE           the corresponding           ach concentratic           ber lot of the SAFE           Results           Regative/Positive           Lot 2           50/0           50/0           50/0           50/0           50/0           50/0           0/50           0/50           0/50           0/50           0/50           0/50           0/50           0/50	at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul g) SAFElife™ T-L n for each lot p ulife™T-Dip Mul g) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 10/40 0/50 0/50 0/50 0/50 0/50
BWP 10         B         -         10         18         10         2         0         95%           Viewer         +         0         0         3         30         10         100%           Viewer         +         0         0         3         30         10         100%           Viewer         +         0         0         3         30         10         100%           BZO         Viewer         +         0         0         3         30         10         100%           BZO         Viewer         +         0         0         1         30         10         100%           BZO         Viewer         +         0         0         1         30         10         100%	AMP 500 AMP 1000 BAR 300	Viewer A Viewer C Viewer A Viewer C Viewer C Viewer B Viewer C Viewer A Viewer C Viewer A	+ - - - - - - - - - - - - - - - - - - -	0 10 0 0 10 0 0 0 10 0 0 0 10 0 0 10 0 0 0 10 0 0 0 10 0 0 0 10 0 0 0 10 0 0 0 10 0 0 0 10 0 0 0 10 0 0 0 10 0 0 0 10 0 0 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	the Cutoff 0 17 0 17 0 17 0 17 0 17 0 17 0 17 0	(Between           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13           1           13           1           10           1           10           2           10           2           10           2           10	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 30 0 28 2 2 28 2 2 28 2 2 28 2 2 28 2 2 2 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 97.5% 97.5% 95% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5%	MET 500 MET 1000 MOP 300 MTD 300	A Viewer B Viewer C Viewer B Viewer A Viewer C Viewer A Viewer C Viewer V V Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer V Viewer V Viewer V V Viewer V Viewer V V V V V V V V V V V V V V V V V V V	-         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10	15           0           15           0           15           0           18	13         2         13         3         12         2         10         2         10         2         10         2         10         2         10         2         10         2         10         12         0         12         2         10         12         2         10         11         2         10         2         10         11         2         10         2         10         11         2         10         2         10         2         10         2         10         2         10         2         10         2         10         2         10         2         10 <td>0           0           20           0           20           0           20           0           20           0           20           0           20           0           24           1           24           1           24           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           28           0           27           1           30           -</td> <td>0 20 0 20 0 15 0 15 0 15 0 15 0 15 0 10 0 10 0 10 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 15 15 15 15 15 15 15 15 15 15</td> <td>95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           95%           90%           90%           90%           90%</td> <td>Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Tes AMP 500</td> <td>Add Sensitivity           ate the precision and ions: cutoff - 100%, cuto &amp; and the cutoff + 100%.           Send the cutoff + 100%.           berformed 2 runs / day and Test Panel. Totally 3 ope           Urine Test Panel. Totally 3 ope           Urine Test Panel. Each of per day), for a total of 50 Test Panel.           t         Approximate Concentration of Sample (ng/mL)           0         125           250         375           500         625           750         875           1000         0           0         0</td> <td>sensitivity, each ff - 75%, cutoff - 5( All concentrations v ad lasted 25 days us irrators participated the 3 operators tes 0 determinations per Number of Determinations per Lot 50 50 50 50 50 50 50 50 50 50</td> <td>drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p <u>(N</u> Lot 1 50/0 50/0 50/0 50/0 11/39 0/50 0/50 0/50 0/50 50/</td> <td>were analyzed , cutoff, cutoff +22 , vith GC/MS or LC the GC/MS or LC the corresponding ach concentratic ber lot of the SAFE Results Results Results SO/0 50/0 50/0 50/0 10/40 0/50 0/50 0/50 0/50 50/0 5</td> <td>at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul g SAFElife™T-D for acd lot p life™T-Dip Mul g) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 50/0 0/50 0/50 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0</td>	0           0           20           0           20           0           20           0           20           0           20           0           20           0           24           1           24           1           24           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           28           0           27           1           30           -	0 20 0 20 0 15 0 15 0 15 0 15 0 15 0 10 0 10 0 10 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 15 15 15 15 15 15 15 15 15 15	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           100%           97.5%           100%           97.5%           100%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           95%           90%           90%           90%           90%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Tes AMP 500	Add Sensitivity           ate the precision and ions: cutoff - 100%, cuto & and the cutoff + 100%.           Send the cutoff + 100%.           berformed 2 runs / day and Test Panel. Totally 3 ope           Urine Test Panel. Totally 3 ope           Urine Test Panel. Each of per day), for a total of 50 Test Panel.           t         Approximate Concentration of Sample (ng/mL)           0         125           250         375           500         625           750         875           1000         0           0         0	sensitivity, each ff - 75%, cutoff - 5( All concentrations v ad lasted 25 days us irrators participated the 3 operators tes 0 determinations per Number of Determinations per Lot 50 50 50 50 50 50 50 50 50 50	drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p <u>(N</u> Lot 1 50/0 50/0 50/0 50/0 11/39 0/50 0/50 0/50 0/50 50/	were analyzed , cutoff, cutoff +22 , vith GC/MS or LC the GC/MS or LC the corresponding ach concentratic ber lot of the SAFE Results Results Results SO/0 50/0 50/0 50/0 10/40 0/50 0/50 0/50 0/50 50/0 5	at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul g SAFElife™T-D for acd lot p life™T-Dip Mul g) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 50/0 0/50 0/50 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/0
Viewer         +         0         0         2         28         10         95%           BZO         Viewer         +         0         0         2         28         10         95%           BZO         Viewer         +         0         0         2         0         95%           BZO         Viewer         +         0         0         11         30         10         100%           BZO         Viewer         +         0         0         1         30         10         100%           BZO         Viewer         +         0         0         1         30         10         100%	АМР 500 АМР 1000 ВАR 300	Viewer A Viewer C Viewer A Viewer C Viewer A Viewer C Viewer C Viewer A Viewer A		0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	the Cutoff 0 17 0 17 0 17 0 17 0 17 0 17 0 16 0 16	(Between           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           13           13           1           10           1           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 30 0 28 2 2 28 2 2 28 2 2 2 9 0 28 1 28 1 28 1 28 2 2 28 2 2 2 2 2 2 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 97.5% 95% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 95% 95%	MET 500 MET 1000 300 MTD 300	A Viewer C Viewer A Viewer C Viewer A Viewer C Viewer C Viewer B Viewer C Viewer A Viewer A	-         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10	15           0           15           0           15           0           18	13         2         13         3         12         2         10         2         10         2         10         2         10         2         10         2         10         12         0         12         0         12         0         12         0         12         0         12         0         12         0         12         10         11         2         10         2         10         2         10         2         10         2         10         2         10         10         10	0           0           20           0           20           0           20           0           20           0           24           1           24           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           28           0           27           1           30           0	0 20 0 20 0 15 0 15 0 15 0 15 0 15 0 10 0 10 0 10 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 15 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 12 0 0 0 12 0 0 0 0 0 0 0 0 0 0 0 0 0	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           100%           97.5%           100%           95%           97.5%           97.5%           100%           95%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           95%           100%           95%           100%           95%           95%	Precision a         To investig         concentrat         cutoff + 75%         study was p         Drug Urine         Multi-Drug         day (2 runs)         Drug Urine         Drug Urine         AMP 500         AMP 1000	A Sensitivity           ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. Deerformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel.           Approximate Concentration of Sample (ng/mL)           0           125           250           375           500           625           750           875           1000           0           250           500	sensitivity, each off - 75%, cutoff - 50 All concentrations v ad lasted 25 days us rators participated the 3 operators tes 0 determinations per 0 determinations per Lot 50 50 50 50 50 50 50 50 50 50 50 50 50	drug samples 7%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p Lot 1 50/0 50/0 50/0 50/0 11/39 0/50 0/50 0/50 0/50 0/50 50/0 50/0 50/	were         analyzed           , cutoff, cutoff +2!           ith GC/MS or LC           th lots of the SAFE           the corresponding           ach concentration           ber lot of the SAFE           legative/Positive           Lot 2           50/0           50/0           50/0           50/0           50/0           50/0           50/0           50/0           50/0           50/0           50/0           50/0           50/0           0/50           0/50           0/50           0/50           50/0           50/0           50/0           50/0           50/0           50/0           50/0           50/0	at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul g SAFElife™ T-Di n for each lot p life™ T-Dip Mul g) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 0/50 0/5
Norm         C	AMP 500 AMP 1000 BAR 300 BUP 10	Viewer A Viewer C Viewer A Viewer B Viewer A Viewer C Viewer C Viewer B Viewer B	+ - - - - - - - - - - - - - - - - - - -	0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	the Cutoff 0 17 0 17 0 17 0 17 0 17 0 16 0 16 0 16	Usetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           13           1           13           1           10           1           10           2           10           2           10           2           10           2           10           10           10           10           10           10           10           10           10	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 28 2 28 2 2 29 0 28 2 29 0 28 2 29 0 28 2 2 29 0 28 1 28 2 28 2 2 2 28 2 2 2 28 2 2 2 2 28 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 95% 100% 97.5% 100% 97.5% 97.5% 95% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 95% 95% 95%	мет 500 МЕТ 1000 300 МТД 300	A Viewer C Viewer A Viewer C Viewer A Viewer C Viewer C Viewer B Viewer C Viewer A Viewer C Viewer V V Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer C Viewer V Viewer V Viewer V Viewer V Viewer V Viewer V Viewer V Viewer V Viewer V V V V V V V V V V V V V V V V V V V	-         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0	15           0           15           0           15           0           18           0	13         2         13         3         12         2         10         2         10         2         10         2         10         0         12         0         12         0         12         0         12         0         12         0         12         0         12         0         12         0         12         0         12         0         12         0         12         10         11         2         10         2         10         2         10         3	0           0           20           0           20           0           24           1           24           1           24           1           24           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           27           1           30           0           30	0 20 0 20 0 15 0 15 0 15 0 15 0 15 0 10 0 10 0 10 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 12 0 15 15 15 15 15 15 15 15 15 15	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           100%           97.5%           100%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           95%           95%           95%           95%           95%           95%           95%           100%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500	Add Sensitivity           ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%. Deerformed 2 runs /day ar Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel.           Approximate Concentration of Sample (ng/mL)           0           125           250           375           500           625           750           875           1000           0           250           500           250           500           500           500           500           500           500           500           500           500	sensitivity, each off - 75%, cutoff - 50 All concentrations v and lasted 25 days us reators participated the 3 operators tes 0 determinations per <b>Number of</b> <b>Determinations</b> <b>per Lot</b> 50 50 50 50 50 50 50 50 50 50	drug samples 7%, cutoff - 25%, vere confirmed wing three differer in the study of t ts 2 aliquots at e concentration p	were analyzed , cutoff, cutoff +21 /ith GC/MS or LC the Corresponding acch concentratic ber lot of the SAFE legative/Positive Lot 2 50/0 50/0 50/0 50/0 10/40 0/50 0/50 0/50 0/50 0/50 50/0 50/0	at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul g SAFElife™ T-Di n for each lot p life™T-Dip Mul s) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 0/50 0/5
BZO         Viewer         +         0         0         2         0         97.5%           OWY         Viewer         +         0         0         97.5%         10         10         10         97.5%           Image: Note of the state of	AMP 500 AMP 1000 BAR 300 BUP 10	Viewer A Viewer B Viewer A Viewer C Viewer C Viewer B Viewer C Viewer A Viewer B Viewer S Viewer C		0 10 0 0 10 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	the Cutoff 0 17 0 17 0 17 0 17 0 16 0 16 0 16 0 16	IBetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           13           1           13           1           10           1           10           1           10           1           10           1           10           1           10           1           10           1           10           1           10           2           10           2           10           2           10           2	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 28 2 2 28 2 2 28 2 2 29 0 0 28 2 2 29 0 0 28 1 1 28 2 1 28 2 2 2 2 2 2 2 2 2 2 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 95% 100% 97.5% 100% 97.5% 97.5% 95% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 95% 95% 95% 95% 95%	MET 500 MET 1000 MOP 300 MTD 300	A Viewer B Viewer C Viewer B Viewer C Viewer A Viewer C Viewer A Viewer B Viewer C Viewer B Viewer B Viewer B Viewer B Viewer C Viewer B Viewer C Viewer B Viewer C Viewer B Viewer C Viewer B Viewer C S Viewer C S Viewer C S Viewer C S Viewer S S Viewer S S Viewer S S Viewer S S S S S S S S S S S S S S S S S S S	-         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10	15           0           15           0           15           0           18	13           2           13           3           12           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           12           0           12           0           12           0           12           0           12           0           12           10           2           10           2           10           2           10           3           9	0           0           20           0           20           0           20           0           20           0           20           0           20           0           24           1           24           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           28           0           27           1           30           0           30           0           30           0	0           20           0           20           0           15           0           15           0           15           0           15           0           10           0           10           0           12           0           12           0           12           0           12           0           12           0           12           0           12           0           10           0           10           0           10           0           10           0           10           0	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           97.5%           97.5%           97.5%           97.5%           100%           97.5%           100%           95%           97.5%           97.5%           97.5%           97.5%           95%           100%           95%           100%           95%           100%           95%           100%           95%           100%           95%           100%           95%           100%           95%           100%           92.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500	Add Sensitivity           ate the precision and ions: cutoff - 100%, cuto 6 and the cutoff + 100%.           6 and the cutoff + 100%.           berformed 2 runs / day ar           Test Panel. Totally 3 ope           Urine Test Panel. Each of per day), for a total of 50           Test Panel.           Concentration of Sample (ng/mL)           0           125           250           375           500           625           750           875           1000           0           0           250           500           500           500           500           500           500           500           0	sensitivity, each off - 75%, cutoff - 5( All concentrations v ad lasted 25 days us irrators participated i the 3 operators tes 0 determinations per Number of Determinations per Lot 50 50 50 50 50 50 50 50 50 50	drug samples 2%, cutoff - 25%, vere confirmed wing three different in the study of t ts 2 aliquots at e concentration p       	were analyzed , cutoff, cutoff +22 , vith GC/MS or LC the Corresponding ach concentratic ber lot of the SAFE Results Regative/Positive Lot 2 50/0 50/0 50/0 50/0 0/50 0/50 0/50 0/5	at the followi \$%, cutoff + 50 /MS method. T life™T-Dip Mul § SAFElife™T-L p Mul b) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 50/0 0/50 0/50 0/50 0/50 0/50 0/50 50/
DLO         Viewei         T         0         0         2         27         10         97.5%           OXY         Viewei         +         0         0         1         30         10         100%         1500         50         0/50         0/50         0/50	AMP 500 AMP 1000 BAR 300 BUP 10	Viewer A Viewer B Viewer A Viewer C Viewer A Viewer B Viewer C Viewer B Viewer C Viewer B Viewer C		0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 0 10 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	the Cutoff 0 17 0 17 0 17 0 17 0 17 0 16 0 16 0 16	IBetween           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13           1           13           1           13           1           10           10           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 30 0 28 2 2 28 2 2 28 2 2 9 0 28 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 8 2 2 2 2 8 2 2 2 2 8 2 2 2 2 8 2 2 2 2 8 2 2 2 2 8 2 2 2 2 8 2 2 2 2 8 2 2 2 2 2 8 2 2 2 2 2 2 2 2 8 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 95% 100% 97.5% 100% 97.5% 100% 97.5% 95% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 95% 95% 95% 95% 95% 95% 95% 95% 95%	MET 500 MET 1000 300 MDP 300 MTD 300	A Viewer B Viewer C Viewer B Viewer C Viewer A Viewer B Viewer C Viewer C Viewer B Viewer B Viewer B Viewer B Viewer B Viewer B Viewer B Viewer B Viewer B Viewer C Viewer B Viewer C Viewer B Viewer C Viewer B Viewer C V V Viewer C Viewer Viewer V V V V V V V V V V V V V V V V V V V	-         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0	15           0           15           0           15           0           18           0	13         2         13         3         12         2         10         2         10         2         10         2         10         2         10         2         10         2         10         12         0         12         0         12         2         10         12         2         10         11         2         10         2         10         2         10         3         9         1	0           20           0           20           0           20           0           20           0           20           0           24           1           24           1           29           1           29           1           29           1           29           1           29           1           29           1           28           0           27           1           27           1           30           0           30           0           30	0           20           0           20           0           15           0           15           0           15           0           15           0           10           0           10           0           10           0           10           0           10           0           12           0           12           0           12           0           12           0           12           0           10           0           10           0           10           0           10           0           10           0           10           0           10	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           100%           97.5%           100%           97.5%           90%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           95%           100%           95%           100%           95%           100%           95%           100%           95%           100%           92.5%           100%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Test AMP 500	Add Sensitivity           ate the precision and ions: cutoff - 100%, cuto & and the cutoff + 100%.           berformed 2 runs / day and Test Panel. Totally 3 ope Urine Test Panel. Each of per day), for a total of 50 Test Panel.           t         Approximate Concentration of Sample (ng/mL)           0         125           250         375           500         625           750         1000           0         0           250         575           1000         0           0         250           500         500           750         1000           0         0           1000         125	sensitivity, each off - 75%, cutoff - 5( All concentrations v ad lasted 25 days us irrators participated i the 3 operators tes 0 determinations per Number of Determinations per Lot 50 50 50 50 50 50 50 50 50 50	drug samples	were analyzed , cutoff, cutoff +2; ith GC/MS or LC th GC/MS or LC the corresponding ach concentratic ber lot of the SAFE <b>Results</b> <b>Results</b> <b>Results</b> <b>Results</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>10</b> <b>1</b>	at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul 9) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 0/50 0/
	AMP 500 AMP 1000 BAR 300 BUP 10	Viewer A Viewer C Viewer A Viewer C Viewer C Viewer C Viewer B Viewer C Viewer B Viewer C Viewer S Viewer		0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 10 0 0 0 10 0 0 0 10 0 0 0 10 0 0 0 0 0 0 0 0 0 0 0 0 0	the Cutoff 0 17 0 17 0 17 0 17 0 17 0 17 0 17 0	(Between           50% below           the cutoff           and the           cutoff)           2           11           12           1           12           1           12           1           13           1           13           1           10           1           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2           10           2	(Between the cutoff and 50% above the cutoff) 30 0 30 0 30 0 30 0 30 0 28 2 2 28 2 2 28 2 2 29 0 28 2 2 28 2 2 28 1 28 2 1 28 2 2 28 2 1 28 2 2 28 2 2 28 2 2 28 2 2 28 2 2 28 2 2 28 2 2 28 2 2 28 2 2 28 2 2 28 2 2 28 2 2 2 28 2 2 2 28 2 2 2 28 2 2 2 28 2 2 2 28 2 2 2 28 2	(Greater than 50% above the cutoff) 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1	with GC/MS or LC/MS 100% 95% 100% 97.5% 100% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 97.5% 95% 95% 95% 95% 95% 95% 95% 95%	MET 500 MET 1000 300 MTD 300 OPI 2000	A Viewer B Viewer C Viewer A Viewer A Viewer A Viewer C Viewer A Viewer C Viewer A Viewer C C Viewer C C Viewer C C Viewer C C Viewer C C Viewer C C Viewer C C Viewer C C Viewer C C Viewer C C C Viewer C C C Viewer C C C C C C C C C C C C C C C C C C C	-         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10           +         0           -         10	15           0           15           0           15           0           18	13         2         13         3         12         2         10         2         10         2         10         2         10         2         10         2         10         2         10         12         0         12         0         12         2         10         11         2         10         2         10         2         10         3         9         1         11	0           0           20           0           20           0           20           0           20           0           20           0           24           1           24           1           24           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           29           1           28           0           27           1           30           0           30           0           30           0           30           0	0           20           0           20           0           15           0           15           0           15           0           15           0           10           0           10           0           10           0           12           0           12           0           12           0           12           0           12           0           10           0           10           0           10           0           10           0           10           0           10           0	95%           100%           95%           100%           92.5%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           95%           97.5%           100%           97.5%           100%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           97.5%           95%           97.5%           95%           100%           95%           100%           95%           100%           95%           100%           92.5%           100%           92.5%           100%           92.5%           100%           92.5%           100%           97.5%	Precision a To investig concentrat cutoff + 75% study was p Drug Urine Multi-Drug day (2 runs Drug Urine Drug Tes AMP 500	Add Sensitivity           ate the precision and ions: cutoff - 100%, cuto & and the cutoff + 100%.           Send the cutoff + 100%, cuto for each of the cutoff + 100%.           Send the cutoff + 100%, cuto and the cutoff + 100%.           Test Panel. Totally 3 ope Urine Test Panel. Totally 3 ope urine Test Panel. Each of per day), for a total of 50 Test Panel.           Approximate Concentration of Sample (ng/mL)           0           125           250           375           500           625           750           1000           0           0           0           0           250           375           500           625           750           1000           250           500           750           1000           1250	sensitivity, each ff - 75%, cutoff - 5( All concentrations v ad lasted 25 days us irrators participated the 3 operators tes 0 determinations per <b>Number of</b> <b>Determinations</b> <b>per Lot</b> 50 50 50 50 50 50 50 50 50 50	drug samples )%, cutoff - 25%, vere confirmed w ing three differer in the study of t ts 2 aliquots at e concentration p (N Lot 1 50/0 50/0 50/0 50/0 11/39 0/50 0/50 0/50 0/50 50/0 50/0 50/0 50/0 50/0 50/0 50/0 0/50	were analyzed , cutoff, cutoff +22 , vith GC/MS or LC the GC/MS or LC the corresponding ach concentratic ber lot of the SAFE <b>Results</b> <b>Results</b> <b>Results</b> <b>Results</b> <b>Results</b> <b>10</b> (700) 50/0 50/0 50/0 50/0 50/0 0/50 0/50 0	at the followi 5%, cutoff + 50 /MS method. T life™T-Dip Mul g SAFElife™T-D m for each lot p life™T-Dip Mul c) Lot 3 50/0 50/0 50/0 50/0 50/0 50/0 50/0 50/

100	А	-	10	18	11	0	0	97.5%
	Viewer	+	0	0	1	29	10	97.5%
	В	-	10	18	11	1	0	97.5%
	Viewer	+	0	0	0	29	10	97.5%
	С	-	10	18	12	1	0	100%
	Viewer	+	0	0	1	28	10	95%
	А	-	10	20	9	2	0	97.5%
PCP	Viewer	+	0	0	1	29	10	97.5%
25	В	-	10	20	9	1	0	97.5%
	Viewer	+	0	0	1	29	10	97.5%
	С	-	10	20	9	1	0	97.5%
	Viewer	+	0	0	2	31	8	97.5%
	А	-	10	17	11	1	0	95%
PPX	Viewer	+	0	0	2	31	8	97.5%
300	В	-	10	17	11	1	0	95%
	Viewer	+	0	0	2	31	8	97.5%
	С	-	10	17	11	1	0	95%
	Viewer	+	0	0	2	29	10	97.5%
	А	-	10	18	10	1	0	95%
TCA	Viewer	+	0	0	2	29	10	97.5%
1000	В	-	10	18	10	1	0	95%
	Viewer	+	0	0	2	29	10	97.5%
	С	-	10	18	10	1	0	95%
	Viewer	+	0	0	2	30	10	100%
	А	-	10	19	9	0	0	95%
тнс	Viewer	+	0	0	2	30	10	100%
50	В	-	10	19	9	0	0	95%
	Viewer	+	0	0	2	30	10	100%
	С	-	10	19	9	0	0	95%

							т
	1750	50	0/50	0/50	0/50		
	2000	50	0/50	0/50	0/50		
BAR 300	0	50	50/0	50/0	50/0		l
	75	50	50/0	50/0	50/0		l
	150	50	50/0	50/0	50/0		
	225	50	50/0	50/0	50/0	MET 500	l
	300	50	8/42	8/42	7/43		I
	375	50	0/50	0/50	0/50		ſ
	450	50	0/50	0/50	0/50		ſ
	525	50	0/50	0/50	0/50		ſ
	600	50	0/50	0/50	0/50		ľ
BUP 10	0	50	50/0	50/0	50/0		ľ
	2.5	50	50/0	50/0	50/0		ľ
	5.0	50	50/0	50/0	50/0		ľ
	75	50	50/0	50/0	50/0	MET 1000	1
	10.0	50	10/40	10/40	9/41		ł
	12.5	50	0/50	0/50	0/50		ł
	15.0	50	0/50	0/50	0/50		ŀ
	175	50	0/50	0/50	0/50		ŀ
	20.0	50	0/50	0/50	0/50		ŀ
P70 700	20.0	50	0/ 50 E0 / 0	0/ 50 E0 /0	0/ 50 F0 / 0		ŀ
BZO 300	U	50	50/0	50/0	50/0		ŀ
	/5	50	50/0	50/0	50/0		ŀ
	150	50	50/0	50/0	50/0	MOD 700	┦
	225	50	50/0	50/0	50/0	MOP 300	ł
	300	50	8/42	7/43	8/42		ł
	375	50	0/50	0/50	0/50		ł
	450	50	0/50	0/50	0/50		ŀ
	525	50	0/50	0/50	0/50		
	600	50	0/50	0/50	0/50		
COC 150	0	50	50/0	50/0	50/0		
	37.5	50	50/0	50/0	50/0		
	75	50	50/0	50/0	50/0		1
	112.5	50	50/0	50/0	50/0	MTD 300	
	150	50	10/40	10/40	10/40		
	187.5	50	0/50	0/50	0/50		
	225	50	0/50	0/50	0/50		
	262.5	50	0/50	0/50	0/50		
	300	50	0/50	0/50	0/50		
COC 300	0	50	50/0	50/0	50/0		
	75	50	50/0	50/0	50/0		
	150	50	50/0	50/0	50/0		ſ
	225	50	50/0	50/0	50/0	OPI 2000	1
	300	50	10/40	10/40	11/39		ľ
	375	50	0/50	0/50	0/50		ľ
	450	50	0/50	0/50	0/50		ŀ
	525	50	0/50	0/50	0/50		ŀ
	600	50	0/50	0/50	0/50		ŀ
EDDP 300	0	50	50/0	50/0	50/0		ŀ
	75	50	50/0	50/0	50/0		
	150	50	50/0	50/0	50/0		ŀ
	225	50	50/0	50/0	50/0	OXV 100	┥
	225	50	0//1	0//0	9//0	041 100	
	300	50	9/41	9/41	0/50		-
	3/5	50	0/50	0/50	0/50		
	450	50	0/50	0/50	0/50		
	525	50	0/50	0/50	0/50		
	600	50	0/50	0/50	0/50		
MDMA	0	50	50/0	50/0	50/0		ļ
500	125	50	50/0	50/0	50/0		ļ
	250	50	50/0	50/0	50/0		╡
	375	50	50/0	50/0	50/0	PCP 25	

	500	50	10/40	10/40	11/39
	625	50	0/50	0/50	0/50
	750	50	0/50	0/50	0/50
	975	50	0/50	0/50	0/50
	1000	50	0/50	0/50	0/50
MET EOO	000	50	0/30 50/0	0/30	0/30 E0/0
ME1 500	125	50	50/0	50/0	50/0
-	125	50	50/0	50/0	50/0
	250	50	50/0	50/0	50/0
	3/5	50	50/0	50/0	50/0
	500	50	10/40	10/40	10/40
	625	50	0/50	0/50	0/50
	750	50	0/50	0/50	0/50
	875	50	0/50	0/50	0/50
	1000	50	0/50	0/50	0/50
MET 1000	0	50	50/0	50/0	50/0
	250	50	50/0	50/0	50/0
	500	50	50/0	50/0	50/0
	750	50	50/0	50/0	50/0
	1000	50	8/42	8/42	7/43
	1250	50	0/50	0/50	0/50
	1500	50	0/50	0/50	0/50
	1750	50	0/50	0/50	0/50
	2000	50	0/50	0/50	0/50
MOP 300	0	50	50/0	50/0	50/0
	75	50	50/0	50/0	50/0
	150	50	50/0	50/0	50/0
	225	50	50/0	50/0	50/0
	300	50	11/39	11/39	11/39
	375	50	0/50	0/50	0/50
	450	50	0/50	0/50	0/50
	525	50	0/50	0/50	0/50
	600	50	0/50	0/50	0/50
MTD 300	0	50	50/0	50/0	50/0
MID 300	75	50	50/0	50/0	50/0
	150	50	50/0	50/0	50/0
	150	50	50/0	50/0	50/0
	225	50	50/0	50/0	50/0
	300	50	8/42	9/41	9/41
	375	50	0/50	0/50	0/50
	450	50	0/50	0/50	0/50
	525	50	0/50	0/50	0/50
	600	50	0/50	0/50	0/50
OPI 2000	0	50	50/0	50/0	50/0
	500	50	50/0	50/0	50/0
	1000	50	50/0	50/0	50/0
	1500	50	50/0	50/0	50/0
	2000	50	10/40	11/39	10/40
	2500	50	0/50	0/50	0/50
	3000	50	0/50	0/50	0/50
	3500	50	0/50	0/50	0/50
	4000	50	0/50	0/50	0/50
OXY 100	0	50	50/0	50/0	50/0
	25	50	50/0	50/0	50/0
	50	50	50/0	50/0	50/0
	75	50	50/0	50/0	50/0
	100	50	8/42	9/41	9/41
	125	50	0/50	0/50	0/50
	150	50	0/50	0/50	0/50
	175	50	0/50	0/50	0/50
	200	50	0/50	0/50	0/50
DCD 25		50	50/0	50/0	50/0
1 OF 20	0	50	30/0	30/0	30/0

	6.25	50	50/0	50/0	50
	12.5	50	50/0	50/0	50
	18.75	50	50/0	50/0	50
	25	50	6/44	6/44	7,
	31.25	50	0/50	0/50	0,
	37.5	50	0/50	0/50	0,
	43.75	50	0/50	0/50	0,
	50	50	0/50	0/50	0,
PPX 300	0	50	50/0	50/0	50
	75	50	50/0	50/0	50
	150	50	50/0	50/0	50
	225	50	50/0	50/0	50
	300	50	10/40	10/40	11
	375	50	0/50	0/50	0,
	450	50	0/50	0/50	0,
	525	50	0/50	0/50	0,
	600	50	0/50	0/50	0,
TCA 1000	0	50	50/0	50/0	50
	250	50	50/0	50/0	50
	500	50	50/0	50/0	50
	750	50	50/0	50/0	50
	1000	50	11/39	10/40	11
	1250	50	0/50	0/50	0,
	1500	50	0/50	0/50	0,
	1750	50	0/50	0/50	0,
	2000	50	0/50	0/50	0,
THC 50	0	50	50/0	50/0	50
	12.5	50	50/0	50/0	50
	25	50	50/0	50/0	50
	37.5	50	50/0	50/0	50
	50	50	11/39	10/40	10
	62.5	50	0/50	0/50	0,
	75	50	0/50	0/50	0,
	87.5	50	0/50	0/50	0,
	100	50	0/50	0/50	0,

# Specificity and Cross Reactivity

To test the specificity of the test, the test device was used to test various drugs, drug metabolites and oth components of the same class that are likely to be present in urine, All the components were added drug-free normal human urine. The following structurally related compounds produced positive results w the test when tested at levels equal to or greater than the concentrations listed below.

Substance	Conc. (ng/mL)	Substance	Conc. (ng/mL)
AMP 500			
d-Amphetamine	500	I-Amphetamine	25,000
d,I-Amphetamine	1,500	(+/-) 3,4- Methylenedioxyamphetamine (MDA)	2,500
Phentermine	1,500	Hydroxyamphetamine	8,000
d-methamphetamine	>100,000	I-methamphetamine	>100,000
(+/-) 3,4- Methylenedioxyethylamphetamin e (MDE)	>100,000	(+/-)3,4- Methylenedioxymethampheta mine (MDMA)	>100,000
Ephedrine	>100,000	β-Phenylethylamine	100,000
Tyramine	100,000	p-Hydroxynorephedrine	100,000
Phenylpropanolamine	>100,000	(±)Phenylpropanolamine	>100,000
d/I-Norephedrine	100,000	Benzphetamine	>100,000
I-Ephedrine	>100,000	I-Epinephrine	>100,000

d/l-Epinephrine				
	>100,000	p - Hydroxyamphetamine	100,000	
AMP 1000				
d-Amphetamine	1,000	I-Amphetamine	50,000	
		(+/-) 3,4-		
d,I-Amphetamine	3,000	Methylenedioxyamphetamine	5,000	
		(MDA)		
Phentermine	3,000	d-Methamphetamine	>100,000	
I-Methamphetamine	>100,000	Ephedrine	>100,000	
(+/-)3,4-				
Methylenedioxymethamphetamin	100,000	Hydroxyamphetamine	8,000	
e (MDMA)				
β-Phenylethylamine	100,000	p-Hydroxynorephedrine	100,000	
Tyramine	100,000	(±)Phenylpropanolamine	>100,000	
Phenylpropanolamine	>100,000	d/I-Norephedrine	100,000	
p-Hydroxyamphetamine	100.000	I-Ephedrine	>100.000	
Benzphetamine	>100.000	d/l-Epinephrine	>100.000	
		3.4 -		
I-Epinephrine	>100.000	Methylenedioxyethylamphetam	>100.000	
1	,	ine (MDE)	,	
BAR 300				
Secobarbital	300	Butathal	100	
Ameharbital	10,000	Butatrial	2500	
Amobarbita	10,000		2,500	
Alphenol	150	Cyclopentobarbital	600	
Aprobarbital	200	Pentobarbital	2,500	
Butabarbital	75	Phenobarbital	10,000	
BUP 10		T		
Buprenorphine	10	Norbuprenorphine	20	
Buprenorphine -3-D-Glucuronide	15	Norbuprenorphine-3-D-	200	
		Glucuronide		
Morphine	>100,000	Oxymorphone	>100,000	
	>100.000			
Hydromorphone	>100,000			
Hydromorphone BZO 300	>100,000			
Hydromorphone BZO 300 Oxazepam	300	Diazepam	200	
Hydromorphone BZO 300 Oxazepam Alprazolam	300 200	Diazepam Estazolam	200 1,000	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam	300 200 1,500	Diazepam Estazolam Flunitrazepam	200 1,000 2,500	
Hydromorphone BZO 300 Oxazepam Alprazolam a-Hydroxyalprazolam Bromazepam	300 200 1,500 500	Diazepam Estazolam Flunitrazepam D,L-Lorazepam	200 1,000 2,500 1,500	
Hydromorphone BZO 300 Oxazepam Alprazolam a-Hydroxyalprazolam Bromazepam Chlordiazepoxide	300 200 1,500 500 1,500	Diazepam Estazolam Flunitrazepam D,L-Lorazepam Midazolam	200 1,000 2,500 1,500 12,500	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam	300 200 1,500 500 1,500 1,500 100	Diazepam Estazolam Flunitrazepam D,L-Lorazepam Midazolam Nitrazepam	200 1,000 2,500 1,500 12,500 4,000	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam	300 200 1,500 500 1,500 100 800	Diazepam Estazolam Flunitrazepam D,L-Lorazepam Midazolam Nitrazepam Norchlordiazepoxide	200 1,000 2,500 1,500 12,500 4,000 200	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Clonazepam Clorazepate dipotassium	300 200 1,500 500 1,500 100 800 200	Diazepam Estazolam Flunitrazepam D,L-Lorazepam Midazolam Nitrazepam Norchlordiazepoxide Norchlordiazepoxide	200 1,000 2,500 1,500 12,500 4,000 200 500	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clobazepam Clonazepam Clorazepate dipotassium Delorazepam	300 200 1,500 500 1,500 100 800 200 1500	Diazepam Estazolam Flunitrazepam D,L-Lorazepam Midazolam Nitrazepam Norchlordiazepoxide Nordiazepam Temazepam	200 1,000 2,500 1,500 12,500 4,000 200 500 250	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate dipotassium Delorazepam Delorazepam	300 200 1,500 500 1,500 100 800 200 1,500 400	Diazepam Estazolam Flunitrazepam D,L-Lorazepam Midazolam Nitrazepam Norchlordiazepoxide Nordiazepam Temazepam Triazolam	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1200	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepam Chlordiazepam Clonazepam Clonazepam Delorazepam Desalkylflurazepam Desanyclifurazepam	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000	Diazepam Estazolam Flunitrazepam D,L-Lorazepam Midazolam Nitrazepam Norchlordiazepoxide Nordiazepam Temazepam Triazolam	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Clonazepate dipotassium Delorazepam Desalkylflurazepam Demoxepam	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Nordiazepam         Temazepam         Triazolam         Flurazepam	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Clonazepate dipotassium Delorazepam Desalkylflurazepam Demoxepam COC 150 Desaga	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000	Diazepam Estazolam Flunitrazepam D,L-Lorazepam Midazolam Nitrazepam Norchlordiazepoxide Nordiazepam Temazepam Triazolam Flurazepam	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Clonazepate dipotassium Delorazepam Desalkylflurazepam Demoxepam COC 150 Benzoylecgonine	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Norchlordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 500	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Clonazepate dipotassium Delorazepate dipotassium Delorazepam Desalkylflurazepam Demoxepam COC 150 Benzoylecgonine Cocaine	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000 150 375	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Norchlordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 16,000 >100,000	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Clonazepam Delorazepam Desalkylflurazepam Demoxepam COC 150 Benzoylecgonine Cocaine Cocaethylene	300 200 1,500 500 1,500 100 800 200 1,500 1,500 2,000 1,500 375 6,250	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Nordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester         Norcocaine	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 16,000 >100,000	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate dipotassium Delorazepam Desalkylflurazepam Demoxepam COC 150 Benzoylecgonine Cocaine Cocaethylene CoC 300	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000 150 375 6,250	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Norchlordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester         Norcocaine	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 16,000 >100,000 >100,000	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate dipotassium Delorazepam Desaklyfflurazepam Desaklyfflurazepam Demoxepam COC 150 Benzoylecgonine Cocaethylene Cocaethylene COC 300 Benzoylecgonine	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000 150 375 6,250	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Nordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester         Norcocaine	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 16,000 >100,000 >100,000	
Hydromorphone BZO 300 Oxazepam Alprazolam Alprazolam Chordiazepam Chlordiazepam Clobazam Clonazepam Clorazepate dipotassium Delorazepam Desalkylflurazepam Demoxepam COC 150 Benzoylecgonine Cocaethylene Cocaoe Benzoylecgonine Cocaine Cocaine	300           200           1,500           500           1,500           100           800           200           1,500           100           800           200           1,500           400           2,000           150           375           6,250           300           750	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Nordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine         Ecgonine         Ecgonine         Ecgonine         Ecgonine         Ecgonine	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 16,000 >100,000 >100,000 >100,000	
Hydromorphone BZO 300 Oxazepam Alprazolam Alprazolam Alprazolam Chordiazepoxide Clobazam Clonazepam Clonazepam Clonazepate dipotassium Delorazepate dipotassium Delorazepam Coco 150 Benzoylecgonine Coccaine Cocaine Cocain	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000 150 375 6,250 300 750 12,500	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Norchlordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester         Norcocaine	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 16,000 >100,000 >100,000 >100,000 >100,000	
Hydromorphone BZO 300 Oxazepam Alprazolam Alprazolam Ghlordiazepoxide Clobazam Clonazepam Clonazepam Clorazepate dipotassium Delorazepate dipotassium Delorazepam Coco 150 Benzoylecgonine Coccaine Coccaethylene Coccaine Cocaethylene Cocaine Cocaethylene EDDP 300	300           300           200           1,500           500           1,500           100           800           200           1,500           400           2,000           150           375           6,250           300           750           12,500	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Norchlordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester         Norcocaine         Ecgonine methyl ester         Norcocaine	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 16,000 >100,000 >100,000 >100,000 >100,000	
Hydromorphone BZO 300 Oxazepam Alprazolam α-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate dipotassium Delorazepam Desalkylflurazepam Demoxepam COC 150 Benzoylecgonine Coccathylene Coccathylene Coccathylene EDDP 300 2-ethylidene-1,5-dimethyl-3,3-	300           300           200           1,500           500           1,500           100           800           200           1,500           400           2,000           150           375           6,250           300           750           12,500	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Norchlordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester         Norcocaine         Ecgonine methyl ester         Norcocaine	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 16,000 >100,000 >100,000 >100,000 >100,000 200,000	
Hydromorphone BZO 300 Oxazepam Alprazolam Alprazolam a-Hydroxyalprazolam Bromazepam Chlordiazepoxide Clobazam Clonazepam Clorazepate dipotassium Delorazepam Desalkylflurazepam Demoxepam COC 150 Benzoylecgonine Cocaine Cocaethylene Cocaethylene EDDP 300 2-ethylidene-1,5-dimethyl-3,3- diphenylpyrrolidine	300           200           1,500           500           1,500           500           1,500           100           800           200           1,500           400           2,000           150           375           6,250           300           750           12,500	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Nordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester         Norcocaine         Ecgonine methyl ester         Norcocaine         Methadone	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 16,000 >100,000 >100,000 >100,000 >100,000	
Hydromorphone BZO 300 Oxazepam Alprazolam	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000 1,500 375 6,250 300 750 12,500 300 300 300,000	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Norchlordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester         Norcocaine         Methadone         Doxylamine	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 16,000 >100,000 >100,000 >100,000 >100,000 >100,000 >100,000	
Hydromorphone BZO 300 Oxazepam Alprazolam Alprazolam Alprazolam Chordiazepam Chlordiazepam Clobazam Clobazam Clonazepam Clorazepate dipotassium Delorazepam Desakylflurazepam Desakylflurazepam Desakylflurazepam CoC 150 Benzoylecgonine Cocatehylene Cocatehylene Cocatehylene EDDP 300 2-ethylidene-1,5-dimethyl-3,3- diphenylpyrolidine EMDP LAAM (Levo-alpha-	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000 1,500 400 2,000 1,500 375 6,250 300 750 12,500	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Norchlordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester         Norcocaine         Methadone         Doxylamine	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 >100,000 >100,000 >100,000 >100,000 >100,000 >100,000 >100,000	
Hydromorphone BZO 300 Oxazepam Alprazolam Alprazolam Chordiazepam Chlordiazepam Clobazam Clobazam Clonazepam Clorazepate dipotassium Delorazepam Desalkylflurazepam Demoxepam COC 150 Benzoylecgonine Coccathylene Coccathylene EDDP 300 2-ethylidene-1,5-dimethyl-3,3- diphenylpyrrolidine EMDP LAAM (Levo-alpha- acetylmethadol) HCl	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000 150 375 6,250 300 750 12,500 300 300,000 >100,000	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Norchlordiazepaxide         Norchlordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester         Norcocaine         Ecgonine methyl ester         Norcocaine         Methadone         Doxylamine         Alpha Methadol	200 1,000 2,500 1,500 12,500 4,000 200 500 250 1,200 500 16,000 >100,000 >100,000 >100,000 >100,000 >100,000 >100,000 >100,000	
Hydromorphone BZO 300 Oxazepam Alprazolam Alprazolam Chordiazepoxide Clobazam Clonazepam Clonazepam Clonazepam Delorazepam Delorazepam Desalkylflurazepam Demoxepam COC 150 Benzoylecgonine Cocathylene Cocathylene EDDP 300 2-ethylidene-1,5-dimethyl-3,3- diphenylpyrrolidine EMDP LAAM (Levo-alpha- acetylmethadol) HCl Disopvramide	300 200 1,500 500 1,500 100 800 200 1,500 400 2,000 150 375 6,250 300 750 12,500 300 750 12,500 300 300,000 >100,000	Diazepam         Estazolam         Flunitrazepam         D,L-Lorazepam         Midazolam         Nitrazepam         Norchlordiazepoxide         Norchlordiazepam         Temazepam         Triazolam         Flurazepam         Ecgonine         Ecgonine methyl ester         Norcocaine         Ecgonine methyl ester         Norcocaine         Methadone         Doxylamine         Alpha Methadol	200 1,000 2,500 1,500 12,500 4,000 200 500 250 12,200 500 16,000 >100,000 >100,000 >100,000 >100,000 >100,000 >100,000	

3,4- Methylenedioxymethamphetamin	500	3,4- Methylenedioxyethylamphetam ine (MDEA)	300
3,4-Methylenedioxyamphetamine	3,000	d-Methamphetamine	>100,000
I-methamphetamine	50,000	l-amphetamine	>100 000
d-amphetamine	>100,000	1 amplietamile	100,000
MET 500	100,000		1
1121 000		(+/_)3/1_	
d-methamphetamine	500	Methylenedioxymethampheta mine (MDMA)	2,000
p-Hydroxymethamphetamine	15,000	(-)-Methamphetamine	12,500
I-methamphetamine	10,000	d-Amphetamine	25,000
I-Amphetamine	37,500	Chloroquine	10,000
(+/-)-Ephedrine	25,000	d/l-Methamphetamine	500
(+/-)3,4- Methylenedioxyamphetamine (MDA)	500	(+/-)3,4Methylenedioxy-n- ethylamphetamine (MDEA)	500
I-Phenylephrine	100,000	β-Phenylethylamine	25,000
Trimethobenzamide	5,000	d/l-Amphetamine	75,000
(1R.2S)-(-)-Ephedrine	50.000	Mephentermine	25.000
MET 1000	,		
d-methamphetamine	1000	l-phenylephrine	>100 000
	30,000	Menhantermine	50,000
I-methamphetamine	25,000	(+/-)3,4-Methylenedioxy-n- ethylamphetamine (MDEA)	1,000
D/L-Methamphetamine	1.000	D-Amphetamine	100.000
	75,000	Chloroquine	50,000
(+/-)-Ephedrine	50,000	(-)-Methamphetamine	25,000
(+/_)3 /	00,000	(+/_)3 /	20,000
Methylenedioxyamphetamine (MDA)	1,000	Methylenedioxymethampheta mine (MDMA)	4,000
β-Phenylethylamine	50,000	Trimethobenzamide	10,000
d,I-Amphetamine	100,000	(1R,2S)-(-)-Ephedrine	100,000
MOP 300			
Morphine	300	Morphinie-3-β-d-glucuronide	1,000
Codeine	300	Norcodeine	6.250
Ethyl Morphine	100	Normorphine	300
Heroin	300	Oxycodone	>100.000
Hydrocodone	5,000	Oxymorphone	10,000
Hydromorphone	1,000	Proceine	150,000
6-Monogcety/morphine (6-MAM)	1,000	Thebaine	3,000
	10.000	meddine	3,000
MTD 300	10,000		
Methadapa	300	Doxulamino	50.000
EMDD	>100.000	EDDD	>100.000
	>100,000	EDDP	>100,000
LAAM	>100,000	Alpha Methadol	>100,000
OPI 2000			
Morphine	2,000	Morphinie-3-β-D-glucuronide	2,000
Codeine	2,000	Norcodeine	12,500
Ethyl Morphine	1,500	Normorphine	50,000
Heroin	2,000	Oxycodone	25,000
Hydrocodone	12,500	Oxymorphone	25,000
Hydromorphone	3,500	Procaine	150,000
6-Monoacetylmorphine (6-MAM)	1,500	Thebaine	5,000
Levorphanol	75,000		
OXY 100			
Oxycodone	100	Codeine	100,000
Dihydrocodeine	20,000	Ethyl Morphine	>100,000
Hydrocodone	10,000	Hydromorphone	32,000
		A second s	A

Oxymorphone	1,000	Thebaine		>100,000	Captopril
Acetylmorphine	>100,000	Morphine		>100,000	Carbamazepine
Buprenorphine	>100,000				Cetradine
PCP 25					Cephalexin
Phencyclidine	25	4-Hydroxypł	nencyclidine	12,500	Chloramphonicol
PPX 300					Chlorothiazido
d-Propoxyphene	300	d-Norpropo	kyphene	300	Cholesterol
TCA 1000					Ciprofloxacin Hydrochloride
Nortriptyline	1,000	Promazine		1,500	Citalopram
Amitriptyline	1,500	Maprotiline		2,000	Clarithromycin
Clomipramine	12,500	Nordoxepin		1,000	Clonidine
Desipramine	200	Promethazin	e	25,000	Clopidoarel Hydroaen Sulpha
Doxepin	2,000	Trimipramine	•	3,000	Clozapine
Imipramine	400	Cyclobenza	orine	800	Conjugated Estrogens
Norclomipramine	12,500				Cortisone
THC 50					Creatinine
11-nor-Δ9-THC-9-COOH	50	Δ9-Tetrahyd	rocannabinol	5,000	(-) Cotinine
( - ) - 11 - nor - 9 - carboxy - △9 - THC	50	Cannabinol		20,000	Chlorpheniramine
11-nor-∆8-THC-9-COOH	30	Cannabidiol		100,000	
11-hydroxy-Δ9-	5,000	11-nor-∆9-Tł	IC-carboxy-	100	D,L-Octopamine
Tetrahydrocannabinol		glucuronide			D,L-Propranolol
Δ8-Tetrahydrocannabinol	1,300				D,L-Tyrosine
:ffect of Urinary Specific Gravity The results demonstrate that the uri	nary specific grav	ity range of 1.000	)~1.035 does not a	ffect the test result.	Deoxycorticosterone Dextromethorphan Diclofenac Diflunisal Digoxin
iffect of Urinary pH					Diphenhydramine
The results demonstrate that the r	and of pH from (	( to 9 door not i	ptorforo with the	porformance of the	Dirithromycin
act	inge of pri nom-	4 10 7 0003 1101 1	interiere with the	benomance of the	
est.					Dulovetine
nterfering Substances					Dicyclomine
The following compounds were add cutoff, and urine with a drug concer	ded to drug-free ntration 25% abov	urine, urine with ve the cutoff for t	a drug concentra he corresponding	tion 25% below the drug of abuse test.	ASSISTANCE
Il potential interferents were adde Iny deviation from the expected re	d at a concentra sults.	tion of 100 μg/m	L. None of the urir	ne samples showed	If you have any question reg 444-3657 (9:00 a.m. to 5:00 p
cetaminophen	Effexor Englapril Malegt	e	Nimodipine Nitroalvcerin		BIBLIOGRAPHY OF SUGG
cetylsalicylic Acid	Ervthromvcin	-	Norethindrone		Baselt, R.C. Disposition of Tox
Acyclovir	Esomeprazole M	agnesium	N-Acetylproco	inamide	Ellenhorn, M.J. and Barceloux
frin	β-Estradiol	0	O-Hydroxvhip	puric Acid	York, 1988.
Albumin (100mg/dL) 1% Ethanol		Olanzapine		Gilman, A. G., and Goodman	

Acetaminophen	Effexor	Nimodipine
Acetophenetidin	Enalapril Maleate	Nitroglycerin
Acetylsalicylic Acid	Erythromycin	Norethindrone
Acyclovir	Esomeprazole Magnesium	N-Acetylprocainamide
Afrin	β-Estradiol	O-Hydroxyhippuric Ac
Albumin (100mg/dL)	1% Ethanol	Olanzapine
Aminophylline	Fenofibrate	Omeprazole
Aminopyrine	Fenoprofen	Oxalic Acid
Amiodarone Hydrochloride	Fentanyl Citrate	Oxolinic Acid
Amlodipine Mesylate	Fluoxetine Hydrochloride	Oxymetazoline
Amoxicillin	Fluvoxamine	Ondansetran
Ampicillin	Furosemide	Paliperidone
Apomorphine	Gabapentin	Pantoprazole
Aripiprazole	Gentisic Acid	Papaverine
Aspartame	Glibenclamide	Paroxetine Hydrochlori
Atomoxetine	Gliclazide	Penfluridol
Atorvastatin Calcium	Glipizide	PenicillinV Potassium
Atropine	Glucose	Penicillin-G
Benzilic Acid	Haloperidol	Phenelzine
Benzoic Acid	Hemoglobin	Pioglitazone Hydrochlo
Bilirubin	Hydrochlorothiazide	Piracetam
Bupropion	Hydrocortisone	Pravastatin Sodium

3-Hydroxytyramine Isosorbide Dinitrate Isoxsuprine Ibuprofen Ketoconazole Ketoprofen Ketamine Kratom powder Labetalol Lamotrigine Levofloxacin Hydrochloride Levonorgestrel bhate Levothyroxine Sodium Lidocaine Hydrochloride Lisinopril Lithium Carbonate Liverite Loperamide Loratadine Magnesium Meperidine Meprobamate Metoprolol Tartrate Mifepristone Mirtazapine Montelukast Sodium Mosapride Citrate Minocycline Nalidixic Acid Naproxen Niacinamide Nifedipine Nikethamide

Prednisone Propylthiouracil Quetiapine Fumarate Quinine Ranitidine Rifampicin Risperidone Salicylic Acid Serotonin Sertraline Hydrochloride Sildenafil Citrate Simvastatin Sodium Valproate Spironolactone Sulfamethazine Sulindac Tetracycline Tetrahydrocortisone 3 acetate Tetrahydrocortisone 3-(β-D glucuronide) Tetrahydrozoline Thiamine Thioridazine Topiramate Tramadol Hydrochloride Trazodone Hydrochloride Triamterene Trifluoperazine Trimethoprim Uric Acid Valproate Verapamil Vitamin B2 Vitamin C

American Council for Drug Education (ACDE) www.acde.org 1-800-488-DRUG

# INDEX OF SYMBOLS



Store between 39°F - 86°F (4°C - 30°C)

Distributed by Wondfo USA Co., Ltd. 545 Willowbrook Centre Parkway, Unit B Willowbrook, IL 60527, USA www.wondfousa.com Made in China

> Rev. A1 Rel.: 2023/08/23

egarding to the use of this product, please call our Toll Free Number 1-888-0 p.m. CDT M-F).

# GESTED READING

	Baselt, R.C. Disposition of Toxic Drugs and Chemicals in Man. Biomedical Publications, Davis, CA, 1982.
nide	Ellenhorn, M.J. and Barceloux, D. G Medical Toxicology. Elservier Science Publishing Company, Inc., New
c Acid	York, 1988.
	Gilman, A. G., and Goodman, L. S. The Pharmacological Fluids, in Martin WR (ed): Drug Addiction I, New
	York, Spring – Verlag, 1977.
	Harvey, R.A., Champe, P.C. Lippincotts Illustrated Reviews. Pharmacology. 91-95, 1992.
	Hawwks RL, CN Chiang. Urine Testing for drugs of Abuse. National Institute for Drug Abuse (NIDA),
	Research Monography 73, 1986.
	Hofmann F.E., A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects, New York, Oxford
	University Press, 1983.
	McBay, A. J. Drug-analysis technologypitfalls and problems of drug testing. Clin. Chem. 33,33B-40B,
	1987.
hloride	
	ADDITIONAL INFORMATION AND RESOURCES

The following list of organizations may be helpful to you for counseling support and resources. These groups also have an Internet address which can be accessed for additional information. National Clearinghouse for Alcohol and Drug Information www.health.org 1-800729-6686 Center for Substance Abuse Treatment <u>www.health.org</u> 1-800-662-HELP The National Council on Alcoholism and Drug Dependence www.ncadd.org 1-800-NCA-CALL

one Hydrochloride